



Public limited company with a capital of 3,505,079.43 euros
Registered office – 49, boulevard du Général Martial Valin – 75015 Paris – France
RCS Paris 410 910 095

DOCUMENTS RELATED TO
THE GENERAL MEETING OF SHAREHOLDERS
OF SEPTEMBER 30, 2025

Translation for information purposes only

This document is a free translation (the “Translation”) of Valerio Therapeutics’ “ASSEMBLÉE GÉNÉRALE DES ACTIONNAIRES DU 30 SEPTEMBRE 2025 - BROCHURE DE CONVOCATION”, dated September 8, 2025. This Translation is provided for convenience and information purposes only. In the event of any ambiguity or conflict between the statements or other items contained herein and the corresponding statements in the French language “ASSEMBLÉE GÉNÉRALE DES ACTIONNAIRES DU 30 SEPTEMBRE 2025 - BROCHURE DE CONVOCATION”, the “ASSEMBLÉE GÉNÉRALE DES ACTIONNAIRES DU 30 SEPTEMBRE 2025 - BROCHURE DE CONVOCATION” shall prevail.

On September 8, 2025

Ladies and gentlemen,

The shareholders are informed that they are invited to a combined general meeting of the shareholders convened on **September 30, 2025 at 2 p.m. CET**, at the registered office of the Company, 49, boulevard du Général Martial Valin – 75015 Paris – France.

Enclosed are the following documents:

- Agenda;
- Text of the resolutions;
- Business Overview;
- Terms of participation in the general meeting;
- Request for the sending of additional documents.

AGENDA

Agenda under the competence of the ordinary general meeting

- management report of the board of directors including the report on corporate governance and presentation by the Board of the annual and consolidated accounts for the year ended 31 December 2024,
- statutory Auditors' reports on the annual and consolidated accounts for the year ended 31 December 2024 and on the agreements referred to in Articles L. 225-38 et seq. of the Commercial Code,
- first resolution: approval of the annual accounts for the year ended 31 December 2024,
- second resolution: approval of the consolidated accounts for the year ended 31 December 2024,
- third resolution: appropriation of results for the year ended 31 December 2024,
- fourth resolution: examination of the agreements referred Articles Article L. 225-38 et seq of the Commercial Code,
- fifth resolution: renewal of the term of office of a member of the board of directors (*Julien Miara*),
- sixth resolution: renewal of the term of office of a member of the board of directors (*Antoine Barouky*),
- seventh resolution: renewal of the term of office of a member of the board of directors (*Jacques Mallet*),
- eighth resolution: authorization to be granted to the board of directors to purchase the Company's own shares,

Agenda under the competence of the extraordinary general meeting

- ninth resolution: delegation of authority to be granted to the board of directors to increase the capital by issuing ordinary shares and/or any other securities, with preferential subscription rights for shareholders, up to a maximum aggregate par value of EUR 24,535,556,
- tenth resolution: delegation of authority to be granted to the board of directors to increase the capital by issuing ordinary shares and/or any other securities, without shareholders' pre-emptive subscription rights, by means of a public offering (other than the offerings referred to in paragraph 1 of Article L. 411-2 of the French Monetary and Financial Code), up to a maximum aggregate par value of EUR 24,535,556,
- eleventh resolution: delegation of authority to be granted to the board of directors to increase the share capital by issuing ordinary shares and/or any other securities, without shareholders' pre-emptive subscription rights, in connection with an offer referred to in paragraph 1 of Article L. 411-2 of the French Monetary and Financial Code,
- twelfth resolution: delegation of authority to be granted to the board of directors to increase the amount of issues with or without pre-emptive rights that would be decided pursuant to resolutions 9 to 11 above, in accordance with the provisions of article L. 225-135-1 of the French Commercial Code,
- thirteenth resolution: delegation of authority to be granted to the board of directors to increase the share capital by issuing ordinary shares or any other securities, without shareholders' pre-emptive

subscription rights, for the benefit of a first category of persons meeting specified characteristics (up to a maximum aggregate par value of EUR 24,535,556 - investors active in the pharmaceutical, healthcare, medical technology or biotechnology sectors),

- fourteenth resolution: delegation of authority to be granted to the board of directors to increase the capital by issuing ordinary shares or any other securities, without shareholders' pre-emptive subscription rights, for the benefit of a second category of persons meeting specified characteristics (up to a maximum aggregate par value of EUR 24,535,556 - industrial companies operating in the pharmaceutical, healthcare, medical technology or biotechnology sectors),
- fifteenth resolution: delegation of authority to be granted to the board of directors to increase the capital immediately or in the future by issuing ordinary shares and/or securities, without shareholders' pre-emptive subscription rights, for the benefit of a category of persons meeting specified characteristics, in the context of an equity or bond financing agreement,
- sixteenth resolution: authorization to be granted to the board of directors to increase the share capital by issuing shares and securities giving access to the Company's capital for the benefit of employees participating in the group's savings plan for the purposes of the capital increase carried out on 21 July 2025, as delegated by the general meeting of 17 July 2025,
- seventeenth resolution: authorization to be granted to the board of directors to increase the share capital by issuing shares and securities giving access to the Company's capital for the benefit of employees participating in the group's savings plan,
- eighteenth resolution: setting the overall limits on the amount of the issues carried out pursuant to resolutions 9 to 17 above,
- nineteenth resolution: authorization to be granted to the board of directors to grant options to subscribe for or purchase shares in the Company in accordance with the provisions of Articles L. 225-177 et seq. of the French Commercial Code,
- twentieth resolution: delegation of authority to be granted to the board of directors to issue and allocate share warrants with cancellation of shareholders' preferential subscription rights in favour of the following categories of persons (i) members of the board of directors of the Company in office on the date of grant of the warrants who are not employees or officers of the Company or any of its subsidiaries and (ii) persons who are bound by a service or consultancy contract with the Company or any of its subsidiaries,
- twenty-first resolution: first authorization given to the Board to proceed with the allotment of existing or new free shares in accordance with articles L. 225-197-1 and following of the Commercial Code,
- twenty-second resolution: second authorization given to the Board to proceed with the allotment of existing or new free shares in accordance with articles L. 225-197-1 and following of the Commercial Code,

Agenda under the competence of the ordinary and extraordinary general meeting

- twenty-third resolution: powers to carry out formalities.

TEXT OF THE RESOLUTIONS

Under the competence of the ordinary general meeting

First resolution

Approval of the company accounts for the financial year ending 31 December 2024

The general meeting, ruling in accordance with the quorum and majority conditions required for ordinary general meetings,

after having acknowledged the management report and the statutory auditors' reports,

approved the annual company accounts for the financial year ending 31 December 2024, as presented to it, in addition to the operations contained in these accounts and summarized in these reports.

Second resolution

Approval of the consolidated accounts for the financial year ending 31 December 2024

The general meeting, ruling in accordance with the quorum and majority conditions required for ordinary general meetings,

after having acknowledged the report from the board of directors on the consolidated accounts for the financial year ending 31 December 2024, and the related statutory auditors' reports,

approved the said consolidated accounts, as presented to it, in addition to the operations contained in these accounts and summarized in these reports.

Third resolution

Allocation of the income for the financial year ended 31 December 2024

The general meeting, ruling in accordance with the quorum and majority conditions required for ordinary general meetings,

after having acknowledged the management report,

noting that the loss from the financial year ending 31 December 2024 amounts to (10,721,021.15) euros,

recalling that the nominal value of the shares was reduced on 21 July 2025 from €0.14 to €0.01 through a reduction in the nominal value of the share capital by €20,067,355.47, this amount having been definitively charged to the 'Retained earnings' account, which was thus reduced from (35,340,967.92) euros to (15,273,612.45) euros,

decides to allocate the loss to the 'retained earnings' account, which is thus increased from (15,273,612.45) euros to (25,994,633.60) euros.

In accordance with the law, the general meeting notes that no dividend has been distributed for the last three financial years.

An application of article 223 quater of the French General Tax Code, the general meeting noted that the Company has assumed no expenses and charges mentioned in article 39-4 of the said code.

Fourth resolution

Examination of the agreements covered by articles L. 225-38 and following of the French Commercial Code

The general meeting, ruling in accordance with the quorum and majority conditions required for ordinary general meetings,

after having reviewed the special report of the statutory auditors on the agreements referred to in Articles L. 225-38 et seq. of the French Commercial Code and ruling on this report,

approves the conclusions of the special report of the statutory auditors and the agreements referred to therein.

Fifth resolution

Renewal of the term of office of a member of the board of directors (Mr Julien Miara)

The general meeting, ruling in accordance with the quorum and majority conditions required for ordinary general meetings,

after having acknowledged the report from the board of directors and noting that Mr Julien Miara's term of office as a board member expires at the end of this meeting,

decided to renew Mr Julien Miara's term of office as a board member for a new three-year period expiring at the end of the ordinary general meeting to be held in 2028 for the purpose of ruling on the accounts from the financial year ending 31 December 2027.

Mr Julien Miara has announced in advance that he accepted the renewal of her term of office as a board member and is not subject to any incompatibility limitations which may prevent him from exercising this position.

Sixth resolution

Renewal of the term of office of a member of the board of directors (Mr Antoine Barouky)

The general meeting, ruling in accordance with the quorum and majority conditions required for ordinary general meetings,

after having acknowledged the report from the board of directors and noting that Mr Antoine Barouky's term of office as a board member expires at the end of this meeting,

decided to renew Mr Antoine Barouky's term of office as a board member for a new three-year period expiring at the end of the ordinary general meeting to be held in 2028 for the purpose of ruling on the accounts from the financial year ending 31 December 2027.

Mr Antoine Barouky has announced in advance that he accepted the renewal of his term of office as a board member and is not subject to any incompatibility limitations which may prevent him from exercising this position.

Seventh resolution

Renewal of the term of office of a member of the board of directors (Mr Jacques Mallet)

The general meeting, ruling in accordance with the quorum and majority conditions required for ordinary general meetings,

after having acknowledged the report from the board of directors and noting that Mr Jacques Mallet's term of office as a board member expires at the end of this meeting,

decided to renew Mr Jacques Mallet's term of office as a board member for a new three-year period expiring at the end of the ordinary general meeting to be held in 2028 for the purpose of ruling on the accounts from the financial year ending 31 December 2027.

Mr Jacques Mallet has announced in advance that he accepted the renewal of his term of office as a board member and is not subject to any incompatibility limitations which may prevent him from exercising this position.

Eighth resolution

Authorization to be granted to the board of directors for the purpose of implementing a share buyback program

The general meeting, ruling in accordance with the quorum and majority conditions required for ordinary general meetings,

after having acknowledged the report from the board of directors,

authorized the board of directors, with the option to sub-delegate in accordance with the conditions stipulated by law, for a period of eighteen (18) months as from today's date, to acquire the Company's shares, in accordance with the conditions stated in articles L. 22-10-62 and following of the French Commercial Code and with (EU) Regulation no. 596/2014 of the European Parliament and Council of April 16, 2014,

decided that the shares may be purchased, sold or transferred by any means and in accordance with the applicable stock-market regulations and the admissible market practices published by the *Autorité des Marchés Financiers* (Financial Markets Authority), including among others:

- by public offer for purchase or exchange,
- by using options or other financial future traded on regulated exchanges, multilateral trading systems, with systematic internalizers or concluded on a private basis or through the awarding of shares following the issuing of securities providing access to the Company's capital through conversion, exchange, reimbursement, the use of a warrant or in any other manner, either directly or indirectly, via a provider of investment services,
- by purchasing blocks of shares or via a multilateral trading system or a systematic internalizer. The portion of the operation which may be performed through block sales is unlimited and may concern the entire operation,

decided that the authorization may be used to:

- ensure the liquidity of the Company's shares as part of the liquidity contract entered into with an investment services provider, in accordance with market practices accepted by the Financial Markets Authority concerning share liquidity contracts;

- fulfil obligations related to stock options, free share allotments, employee savings plans or other share allocations to employees and managers of the Company or of the companies linked to it;
- provide shares during the exercising of rights attached to securities providing access to the share capital;
- purchase shares for conservation and subsequent exchange or as payment for any possible external growth operations, in compliance with stock market regulations, among others;
- cancel all or part of the shares thus purchased; or
- more generally, to take action concerning any objective authorized by law or any market practice accepted by the market authorities, with it being hereby specified that in such a hypothesis, the Company shall inform its shareholders by means of an announcement;

decided to set the maximum unitary purchase price per share (excluding costs and commission) at 3 euros, with an overall ceiling of 1,000,000 euros, with it being hereby specified that this purchase price will be subject to adjustments when necessary in order to take account of operations concerning the share capital (including in the cases of the incorporation of reserves and the free allocation of shares, or the division or consolidation of shares) occurring during the validity period of this authorization,

decided that the maximum number of shares which can be purchased under the terms of this resolution may at no time exceed 10% of the total number of shares comprising the share capital at any given moment, with this percentage applying to the share capital adjusted in accordance with the operations affecting it after this general meeting, with it being hereby specified that (i) when the shares are acquired for the purpose of supporting the liquidity of the Company's shares in accordance with the conditions stipulated by the general rules of the Financial Markets Authority, the number of shares taken into account for the calculation of this limit shall correspond to the number of shares purchased following the deduction of the number of shares resold during the authorization period and (ii) when they are acquired with a view to retaining them and subsequently using them as payment or exchange as part of a merger, spin-off or contribution operation, the number of shares acquired may not exceed 5% of the total number of shares,

granted full powers to the board of directors with the option to sub-delegate in accordance with the conditions provided for by law, for the purpose of implementing this authorization, and in particular for considering the appropriateness of initiating a buyback program and to determine the terms and conditions thereof, to place any stock exchange orders, sign any assignment or transfer documents, conclude any agreement, any liquidity contract, any option contracts, submit any declarations to the Financial Markets Authority or any other organization, and any other formalities required, including to allocate or reallocate the acquired shares for the relevant formalities and, more generally, to do everything necessary.

decided that these operations may not be performed during periods when public offerings are underway concerning the Company's shares.

This authorization invalidates the unused portion of any previous authorization granted to the board of directors for the purpose of carrying out operations concerning the Company's shares.

Under the competence of the extraordinary general meeting

Ninth resolution

Delegation of authority to be granted to the board of directors to increase the capital by issuing ordinary shares and/or any other securities, with preferential subscription rights for shareholders, up to a maximum aggregate par value of EUR 24,535,556

The general meeting, ruling in accordance with the quorum and majority conditions required for extraordinary general meetings and noting that the capital is fully paid up,

after having acknowledged the report from the board of directors and the statutory auditors' reports,

in accordance with the provisions of articles L. 225-129 and following of the French Commercial Code, and in particular its articles L. 225-129 to L. 225-129-6, L. 22-10-49, L. 225-132, L. 225-133, L. 225-134, L. 228-91, L. 228-92 and L. 228-93,

delegated its authority to the board of directors, with the option of delegation or sub-delegation, in accordance with the legal conditions, for the purpose of deciding, in the proportions and at the times of its choosing, on one or several capital increases through the issuing in France and abroad of ordinary shares in the Company or equity securities providing access to other equity securities or creating a right to the allocation of debt securities and/or other securities (including all debt securities) providing access to the Company's equity securities or those of any company directly or indirectly possessing more than half its equity or in which it directly or indirectly holds more than half the equity, with the possibility for the said securities to be issued in euros, in foreign currency or in any monetary units established by reference to several currencies at the choice of the board of directors, the payment for which may be in cash, including through the offsetting of receivables,

decided that the maximum nominal value of the capital increases which may be performed, immediately and/or in the future under the terms of this resolution, is set at 24,535,556 euros (or the equivalent of this amount in the case of an issue in another currency), which represents 2,453,555,600 shares on the basis of the current nominal value, i.e., approximately 700% of the share capital as of July 31, 2025,

with it being hereby stipulated that:

- the maximum nominal value of the capital increases which may be performed immediately or in the future under the terms of this delegation will be deducted from the overall ceiling provided for in the eighteenth resolution below,
- to these ceilings should be added, where applicable, the par value of the shares to be issued to maintain the rights of the bearers of securities and other rights providing access to the share capital, in accordance with the law and where applicable the relevant contractual clauses,

decided to set at 24,535,556 euros (or the equivalent of this amount in the case of an issue in another currency) the maximum nominal value of the debt securities which may be issued under the terms of this delegation with it being hereby stipulated that:

- this amount will be increased, where applicable, by any redemption premium above the par value,
- this amount will be deducted from the overall ceiling mentioned in the eighteenth resolution below,
- this ceiling does not apply to the debt securities mentioned in articles L. 228-40, L. 228-36-A and L. 228-92 paragraph 3 of the French Commercial Code, the issuing of which will be decided or authorized by the board of directors in accordance with the conditions stated in article L. 228-40 of the French Commercial Code or, in the other cases, the conditions determined by the Company in accordance with the provisions of article L. 228-36- A of the French Commercial Code,

decided that the shareholders may exercise their preferential subscription rights for shares and securities issued under the terms of this resolution in accordance with the applicable legal and statutory provisions,

decided that the board of directors may introduce a reducible subscription right for shareholders which may be exercised in proportion to their rights and up to the amounts requested by them,

decided that if the irreducible and where applicable reducible subscriptions have not absorbed the whole issue, the board of directors may use one or other of the following options, in the order it considers most appropriate:

- limit the issue to the value of the subscriptions received on condition that this is not less than three quarters of the initial issue value concerned, as decided by the board of directors,
- distribute, without restriction, all or part of the unsubscribed shares on an irreducible basis and, where applicable, on a reducible basis,
- offer all or part of the unsubscribed shares to the public,

decided that the issues of the Company's share warrants may be performed by cash subscriptions but also through free allocation to the owners of the former shares,

decided that in the case of the free allocation of share warrants, the board will have the option to decide that the allocation rights forming odd lots will not be tradable and that the corresponding shares will be sold,

acknowledged, as required, that regarding the bearers of securities possibly issued under the terms of this delegation, this delegation constitutes an express renunciation by the shareholders of their preferential subscription rights to the shares to which these securities create an entitlement,

decided that the board will have full powers to implement this delegation in accordance with the conditions set by the law and the articles of incorporation, for the purpose, among others, without this list being in anyway restrictive, of setting the dates, terms and conditions of any issue in addition to the form and characteristics of the shares or securities providing access to the capital or debt securities to be issued, with or without premium. Among other things, it will determine the amounts to be issued, the dividend date, which may possibly be retroactive, of the shares or securities providing access the capital or debt securities to be issued, the means by which they are to be paid up and, where applicable, the duration and exercise prices of the securities or the means of exchange, conversion, reimbursement or allocation in any other manner of capital securities and other securities providing access to the capital within the limits provided for in this resolution,

decided that the board of directors will possess full powers with the option of delegation and sub-delegation, to implement this delegation and to proceed, in one or several stages and in the proportions and at the times it shall determine, with the above-mentioned issues - or postpone doing so if necessary - to enter into all agreements to complete the contemplated issues, to confirm their completion and to proceed with the related modifications to the articles of incorporation, and more generally:

- determine the terms for the adjustment of the conditions for accessing the capital and securities in the future, in accordance with legal requirements;
- where necessary, suspend the exercising of rights attached to these securities for a maximum period of three (3) months;
- arrange all deductions from the premiums, including those for the costs incurred for the performance of the issues;
- subsequently ensure the preservation of the rights of the bearers of securities providing future access to the Company's capital, issued in application of this delegation, in compliance with the legal and statutory provisions, and, where necessary, the applicable contractual clauses;

- take all measures and complete all required formalities to have the securities thus issued listed on the Euronext Paris regulated exchange and any other exchange on which the Company's shares would then be traded,

decided that this delegation may not be used during periods when public offerings are underway concerning the Company's shares.

acknowledged that in the event that the board of directors uses the delegation of authority granted to it under the terms of this resolution, it will report back to the next ordinary general meeting in accordance with the law and the regulations,

decided that this delegation is granted for a period of twenty-six (26) months as from the date of this meeting, rendering any previous delegation concerning the same subject invalid.

Tenth resolution

delegation of authority to be granted to the board of directors to increase the capital by issuing ordinary shares and/or any other securities, without shareholders' pre-emptive subscription rights, by means of a public offering (other than the offerings referred to in paragraph 1 of Article L. 411-2 of the French Monetary and Financial Code), up to a maximum aggregate par value of EUR 24,535,556

The general meeting, ruling in accordance with the quorum and majority conditions required for extraordinary general meetings,

after having acknowledged the report from the board of directors and the statutory auditors' reports,

in accordance with the provisions of articles L. 225-129 and following of the French Commercial Code, and in particular its articles L. 225-129 to L. 225-129-6, L. 22-10-49, L. 225-135, L. 225 235-1, L. 225-136, L. 228-91, L. 228-92 and L. 228-93,

delegated its authority to the board of directors, with the option of delegation or sub-delegation, in accordance with the legal conditions, for the purpose of deciding, by means of a public offering to the exclusion of the public offerings mentioned in paragraph 1° of article L. 411-2 of the French Monetary and Financial Code, on the issuing in one or several stages in France and abroad, in the proportions and at the time of its choosing, of ordinary shares in the Company or equity securities providing access to other equity securities or creating a right to the allocation of debt securities and/or other securities (including all debt securities) providing access to the Company's equity securities or those of any company directly or indirectly possessing more than half its equity or in which it directly or indirectly holds more than half the equity, with the possibility for the said securities to be issued in euros, in foreign currency or in any monetary units established by reference to several currencies at the choice of the board of directors, the payment for which may be in cash, including through the offsetting of receivables,

decided that the securities thus issued may consist of equity securities, be associated with the issuing of such securities or allow for the issue thereof as intermediate securities,

decided to remove the shareholders' preferential right of subscription concerning the ordinary shares or securities issued under the terms of this delegation,

decided that a priority subscription right shall be established for the shareholders concerning all or part of the issues based on the period and the terms it specifies in accordance with the provisions of article L. 22-10-51 of the French Commercial Code, with this priority not resulting in the creation of tradable rights though it may be exercised either on an irreducible or reducible basis,

acknowledged, as required, that regarding the bearers of securities possibly issued under the terms of this delegation, this delegation constitutes an express renunciation by the shareholders of their preferential subscription rights to the shares to which these securities create an entitlement,

decided that the maximum nominal value of the capital increases which may be performed, immediately and/or in the future under the terms of this resolution, is set at 24,535,556 euros (or the equivalent of this amount in the case of an issue in another currency), which represents 2,453,555,600 shares on the basis of the current nominal value, i.e., approximately 700% of the share capital as of July 31, 2025,

with it being hereby stipulated that:

- the maximum nominal value of the capital increases which may be performed immediately or eventually under the terms of this delegation will be deducted from the overall ceiling provided for in the eighteenth resolution below,
- to these ceilings should be added, where applicable, the par value of the shares to be issued to maintain the rights of the bearers of securities and other rights providing access to the share capital, in accordance with the law and where applicable the relevant contractual clauses,

decides to set at 24,535,556 euros (or the equivalent of this amount in the case of an issue in another currency) the maximum nominal value of the debt securities which may be issued under the terms of this delegation with it being hereby stipulated that:

- this amount will be increased, where applicable, by any redemption premium above the par value,
- this amount will be deducted from the overall ceiling mentioned in the eighteenth resolution below,
- this ceiling does not apply to the debt securities mentioned in articles L. 228-40, L. 228-36-A and L. 228-92 paragraph 3 of the French Commercial Code, the issuing of which will be decided or authorized by the board of directors in accordance with the conditions stated in article L. 228-40 of the French Commercial Code or, in the other cases, the conditions determined by the Company in accordance with the provisions of article L. 228-36- A of the French Commercial Code,

decided that if the subscriptions have not absorbed the whole issue, the board of directors may use one or other of the following options, the order to be determined by it:

- limit the issue to the value of the subscriptions, on condition that this is not less than three quarters of the issue value initially decided,
- distribute all or part of the unsubscribed securities issued among the persons of its choice without restriction, and
- offer all or part of the unsubscribed securities issued to the public, in the French international markets,

decided that the issue price for the shares to be issued under the terms of this delegation will be set by the board of directors and will be at least equal to the average market rate weighted by the volumes from the last three stock-market sessions preceding the setting of the issue price, possibly reduced by a maximum of 25% (with it however being specified that if, when using this delegation, the Company's shares were admitted for trading in a regulated exchange, the price would be set in accordance with the provisions of articles L. 22-10-52 and R. 22-10-32 of the French Commercial Code), taking account, where applicable, of their dividend date; with it being hereby specified that (i) in the event of the issuing of securities providing access to the capital, the issue price for the shares resulting from their use, their conversion or their exchange may where applicable be set at the board's discretion with reference to a calculation formula defined by it and applicable after the issuing of the said securities (for example when

exercising, converting or exchanging them) in which case the above-mentioned maximum reduction may be assessed, if the board considers it appropriate, on the application date of the said formula (and not the date on which the price is set for the issuing of the securities) and (ii) the issue price of securities providing access to the capital possibly issued under the terms of this resolution will be such that the sum received, where applicable, immediately by the Company, increased by that likely to be received by it when exercising or converting the said securities, will be at least equal to the above-mentioned minimum sum for each share issued as a consequence of the issuing of these securities, decided that this delegation is granted for a period of twenty-six (26) months as from the date of this meeting, ending any previous delegation concerning the same subject,

decided that the board of directors will possess full powers with the option of sub-delegation as stipulated by law, to implement this delegation in accordance with the conditions specified by law and in the articles of incorporation, for the following purposes among others:

- specify the dates, terms and conditions for any issue in addition to the form and characteristics of the shares or securities providing access to the capital to be issued, with or without premiums,
- determine the amounts to be issued, the dividend date, which may possibly be retroactive, of the shares or securities providing access the capital to be issued, the means by which they are to be paid up and, where applicable, the conditions for exercising the exchange, conversion, redemption or other allocation rights of capital securities and other securities providing access to the capital,
- carry out any required adjustments in application of the legal or statutory provisions and, where necessary, the applicable contractual clauses to protect the rights of bearers of securities and other rights providing access to the Company's capital and
- where necessary, suspend the exercising of rights attached to these securities for a maximum period of three (3) months,

decided that the board of directors may:

- at its own initiative and when it considers it appropriate, deduct the costs, duties and fees arising from the capital increases performed under the terms of the delegation mentioned in this resolution from the total premiums related to these operations and deduct from these premiums the sums required to bring the legal reserve up to one tenth of the new share capital, after each operation,
- take any decision with a view to having the shares and securities thus issued traded on the Euronext Growth exchange in Paris or any other exchange, whether regulated or otherwise, in France or abroad, and more generally,
- take all measures, enter into all commitments and carry out all formalities contributing to the successful completion of the proposed issue and for the purpose of making the resulting capital increase permanent, and amend the articles of incorporation accordingly.

decided that this delegation may not be used during periods when public offerings are underway concerning the Company's shares.

Eleventh resolution

delegation of authority to be granted to the board of directors to increase the share capital by issuing ordinary shares and/or any other securities, without shareholders' pre-emptive subscription rights, in connection with an offer referred to in paragraph 1 of Article L. 411-2 of the French Monetary and Financial Code

The general meeting, ruling in accordance with the quorum and majority conditions required for extraordinary general meetings,

after having acknowledged the report from the board of directors and the statutory auditors' reports,

in accordance with the provisions of articles L. 225-129 and following of the French Commercial Code, and in particular its articles L. 225-129-2, L. 225-135, L. 225-135-1, L. 225-136, L. 228-91, L. 228-92 and L. 228-93 and L. 22-10-49 of the French Commercial Code,

delegated its authority to the board of directors, with the option of sub-delegation, in accordance with the legal conditions, for the purpose of deciding, by means of an offering mentioned in paragraph 1° of article L. 411-2 of the French Monetary and Financial Code, on the issuing in one or several stages in France and abroad, in the proportions and at the time of its choosing, of ordinary shares in the Company or equity securities providing access to other equity securities or creating a right to the allocation of debt securities and/or other securities (including all debt securities) providing access to the Company's equity securities or those of any company directly or indirectly possessing more than half its equity or in which it directly or indirectly holds more than half the equity, with the possibility for the said securities to be issued in euros, in foreign currency or in any monetary units established by reference to several currencies at the choice of the board of directors,

decided that the securities thus issued may consist of equity securities, be associated with the issuing of such securities or allow for the issue thereof as intermediate securities,

decided to remove the shareholders' preferential right of subscription concerning the ordinary shares or securities issued under the terms of this delegation,

acknowledged, as required, that regarding the bearers of securities possibly issued, this delegation constitutes an express renunciation by the shareholders of their preferential subscription rights to the shares to which these securities create an entitlement,

decided that the maximum nominal value of the share capital increases which may be performed, immediately and/or in the future under the terms of this resolution, may neither exceed 701,015.89 euros (or the equivalent of this amount in the case of an issue in another currency), which represents 70,101,589 shares on the basis of the current nominal value, i.e., approximately 20% of the share capital as of July 31, 2025,

nor under any circumstances exceed the limits provided for in the regulations applicable on the issue date (for information purposes, on the date of this meeting the issuing of equity securities performed by means of an offering mentioned in paragraph of paragraph 1° of article L. 411-2 of the French Monetary and Financial Code is limited to 20% of the Company's capital per 12-month period, with the said capital being assessed on the date of the board's decision to use this delegation), a maximum amount to which must be added, where applicable, the additional sum of the shares to be issued in order to maintain the rights of the bearers of securities providing access to the capital and other rights providing access to the capital in accordance with the provisions of the law and where applicable the contractual clauses,

furthermore decided that the nominal value of any increase in share capital which may be performed will be deducted from the overall ceiling mentioned in the eighteenth resolution below,

decided to set at 701,015.89 euros (or the equivalent of this amount in the case of an issue in another currency) the maximum nominal value of the debt securities which may be issued under the terms of this delegation with it being hereby stipulated that:

- this amount will be increased, where applicable, by any redemption premium above the par value,

- this amount will be deducted from the overall ceiling mentioned in the eighteenth resolution below,
- this ceiling does not apply to the debt securities mentioned in articles L. 228-40, L. 228-36-A and L. 228-92 paragraph 3 of the French Commercial Code, the issuing of which will be decided or authorized by the board of directors in accordance with the conditions stated in article L. 228-40 of the French Commercial Code or, in the other cases, the conditions determined by the Company in accordance with the provisions of article L. 228-36- A of the French Commercial Code,

decided that if the subscriptions have not absorbed the whole issue, the board of directors may use one or other of the following options, the order to be determined by it:

- limit the issue to the value of the subscriptions, on condition that this is not less than three quarters of the issue value initially decided,
- distribute all or part of the unsubscribed securities issued among the persons of its choice without restriction,

decided that the issue price for the shares to be issued under the terms of this delegation will be set by the board of directors and will be at least equal to the average market rate weighted by the volumes from the last three stock-market sessions preceding the setting of the issue price, possibly reduced by a maximum of 25% (with it however being specified that if, when using this delegation, the Company's shares were admitted for trading in a regulated exchange, the price would be set in accordance with the provisions of articles L. 22-10-52 and R. 22-10-32 of the French Commercial Code), taking account, where applicable, of their dividend date; with it being hereby specified that (i) in the event of the issuing of securities providing access to the capital, the issue price for the shares resulting from their use, their conversion or their exchange may, where applicable, be set at the board's discretion with reference to a calculation formula defined by it and applicable after the issuing of the said securities (for example when exercising, converting or exchanging them) in which case the above-mentioned maximum reduction may be assessed, if the board considers it appropriate, on the application date of the said formula (and not the date on which the price is set for the issuing of the securities) and (ii) the issue price of securities providing access to the capital possibly issued under the terms of this resolution will be such that the sum received, where applicable, immediately by the Company, increased by that likely to be received by it when exercising or converting the said securities, will be at least equal to the above-mentioned minimum sum for each share issued as a consequence of the issuing of these securities,

decided that this delegation is granted for a period of twenty-six (26) months as from the date of this meeting, ending any previous delegation concerning the same subject,

decided that the board of directors will have full powers with the option of delegation and sub-delegation as stipulated by law, to implement this delegation in accordance with the conditions specified by law and in the articles of incorporation, for the following purposes among others:

- specify the dates, terms and conditions for any issue in addition to the form and characteristics of the shares or securities providing access to the capital to be issued, with or without premiums,
- determine the amounts to be issued, the dividend date, which may possibly be retroactive, of the shares or securities providing access the capital to be issued, the means by which they are to be paid up and, where applicable, the conditions for exercising the exchange, conversion, redemption or other allocation rights of capital securities and other securities providing access to the capital,

- carry out any required adjustments in application of the legal or statutory provisions and, where necessary, the applicable contractual clauses to protect the rights of bearers of securities and other rights providing access to the Company's capital and
- where necessary, suspend the exercising of rights attached to these securities for a maximum period of three (3) months,

decided that the board of directors may:

- at its own initiative and when it considers it appropriate, deduct the costs, duties and fees arising from the capital increases performed under the terms of the delegation mentioned in this resolution from the total premiums related to these operations and to deduct from these premiums the sums required to bring the legal reserve up to one tenth of the new share capital, after each operation,
- take any decision with a view to having the shares and securities thus issued traded on the Euronext Growth exchange in Paris or any other exchange, whether regulated or otherwise, in France or abroad, and more generally,
- take all measures, enter into all commitments and carry out all formalities contributing to the successful completion of the proposed issue and for the purpose of making the resulting capital increase permanent, and amend the articles of incorporation accordingly,

decided that this delegation may not be used during periods when public offerings are underway concerning the Company's shares.

Twelfth resolution

delegation of authority to be granted to the board of directors to increase the amount of issues with or without pre-emptive rights that would be decided pursuant to resolutions 9 to 11 above, in accordance with the provisions of article L. 225-135-1 of the French Commercial Code

The general meeting, ruling in accordance with the quorum and majority conditions required for extraordinary general meetings,

after having acknowledged the report from the board of directors and the statutory auditors' reports,

in accordance with the provisions of articles L. 225-129 to L. 225-129-2, L. 225-135, L. 228-91, L. 228-92 and L. 228-93 of the French Commercial Code,

delegated its authority to the board of directors for the purpose of increasing the value of the issues with preferential subscription rights to be decided on under the terms of the ninth resolution, tenth resolution and eleventh resolution above, in accordance with the conditions mentioned in article L. 225-135-1 of the French Commercial Code, i.e., currently within 30 days of the closure of the subscription, at the same price as that adopted for the initial issue and subject to a limit of 15% of the initial issue), with the said shares granting the same rights as the former shares subject to their dividend date,

decided that the nominal value of the capital increases decided on in this resolution will be deducted from the overall ceiling mentioned in the eighteenth resolution below, a sum to which shall be added, where applicable, the additional value of the additional shares or securities to possibly be issued to maintain the rights of the bearers of securities and other rights providing access to the share capital, in accordance with the law and where applicable the relevant contractual clauses,

acknowledged that in the event that the board of directors uses the delegation of authority granted to it under the terms of this resolution, it will report back to the next ordinary general meeting in accordance

with the law and the regulations,

decided that this delegation may not be used during periods when public offerings are underway concerning the Company's shares,

decided that this delegation is granted for a period of twenty-six (26) months as from the date of this meeting.

Thirteenth resolution

delegation of authority to be granted to the board of directors to increase the share capital by issuing ordinary shares or any other securities, without shareholders' pre-emptive subscription rights, for the benefit of a first category of persons meeting specified characteristics (up to a maximum aggregate par value of EUR 24,535,556 - investors active in the pharmaceutical, healthcare, medical technology or biotechnology sectors)

The general meeting, ruling in accordance with the quorum and majority conditions required for extraordinary general meetings,

after having acknowledged the report from the board of directors and the statutory auditors' reports,

in accordance with the provisions of articles L. 225-129 and following of the French Commercial Code and particularly its articles L. 225-129-2, L. 22-10-49, L. 225-135, L-225-138 and L. 228-91 and following of the French Commercial Code,

delegated its authority to the board of directors, for the purpose of deciding on the issuing, in one or several stages, in the proportions and at the times of its choosing, in France or abroad, in euros, in foreign currency or in any monetary units established by reference to several currencies, of ordinary shares in the Company or equity securities providing access to other equity securities or creating a right to the allocation of debt securities, and/or other securities (including all debt securities) providing access to the Company's equity securities (including in particular share subscription warrants or share issuance rights),

decided that the securities thus issued may consist of equity securities, be associated with the issuing of such securities or allow for the issue thereof as intermediate securities,

decided to remove the shareholders' preferential subscription rights to the Company's ordinary shares and/or other securities and/or all debt securities to be issued for the benefit of the following category of persons:

- natural or legal persons, foundations, companies or investment funds, whether or not they are shareholders of the Company, investing primarily or having invested, directly or indirectly, over the past thirty-six (36) months in "small caps" or "mid caps" growth companies (i.e., whose capitalization when listed does not exceed 1,000,000,000 euros) (including, without limitation, investment funds or venture capital companies, notably any FPCI, FCPI or FIP) in the pharmaceutical, healthcare, medical technology or biotechnology sectors, and/or
- natural or legal persons, foundations, companies, trusts, investment funds or other investment vehicles of any kind, whether or not they are shareholders of the Company, under French or foreign law, investing, directly or indirectly, on a regular basis in the pharmaceutical, healthcare, medical technology or biotechnology sectors, and/or
- natural or legal persons, foundations, companies, institutions, entities, trusts, investment funds or other investment vehicles of any kind, whether governed by French or foreign law, on the

occasion of the conclusion of an industrial, commercial, licensing, research or partnership agreement with the Company,

acknowledged, as required, that regarding the bearers of securities possibly issued, this delegation constitutes an express renunciation by the shareholders of their preferential subscription rights to the shares to which these securities create an entitlement,

decided that the maximum nominal value of the share capital increases which may be performed, immediately and/or in the future under the terms of this delegation, may not exceed 24,535,556 euros (or the equivalent of this amount in the case of an issue in another currency), which represents 2,453,555,600 shares on the basis of the current nominal value, i.e., approximately 700% of the share capital as of July 31, 2025,

being a maximum amount to which must be added, where applicable, the additional sum of the shares to be issued in order to maintain the rights of the bearers of securities providing access to the capital and other rights providing access to shares in accordance with the legal and regulatory provisions and where applicable the contractual clauses,

furthermore decided that the nominal value of any increase in share capital which may be performed will be deducted from the overall ceiling mentioned in the eighteenth resolution below,

decided to set at 24,535,556 euros (or the equivalent of this amount in the case of an issue in another currency) the maximum nominal value of the debt securities which may be issued under the terms of this delegation with it being hereby stipulated that:

- this amount will be increased, where applicable, by any redemption premium above the par value,
- this amount will be deducted from the overall ceiling mentioned in the eighteenth resolution below,
- this ceiling does not apply to the debt securities mentioned in articles L. 228-40, L. 228-36-A and L. 228-92 paragraph 3 of the French Commercial Code, the issuing of which will be decided or authorized by the board of directors in accordance with the conditions stated in article L. 228-40 of the French Commercial Code or, in the other cases, the conditions determined by the Company in accordance with the provisions of article L. 228-36- A of the French Commercial Code,

decided that the issue price for the shares issued under the terms of this delegation will be determined by the board of directors and will be at least equal to the average market rate weighted by the volumes from the last three stock-market sessions preceding the setting of the issue price, possibly reduced by a maximum of 25%, taking account, where applicable, of their dividend date; with it being hereby specified that (i) in the event of the issuing of securities providing access to the capital, the issue price for the shares resulting from their use, their conversion or their exchange may, where applicable, be set at the board of directors' discretion with reference to a calculation formula defined by it and applicable after the issuing of the said securities (for example when exercising, converting or exchanging them) in which case the above-mentioned maximum reduction may be assessed, if the board considers it appropriate, on the application date of the said formula (and not the date on which the price is set for the issue) and (ii) the issue price of securities providing access to the capital possibly issued under the terms of this resolution will be such that the sum received, where applicable, immediately by the Company, increased by that likely to be received by it when exercising or converting the said securities, will be at least equal to the above-mentioned minimum sum for each share issued as a consequence of the issuing of these securities,

specified that this delegation is granted for a period of eighteen (18) months as from the date of this meeting, ending any previous delegation concerning the same subject,

decided that the board of directors will have full powers with the option of delegation and sub-delegation as stipulated by law, to implement this delegation in accordance with the conditions specified by law and in the articles of incorporation, for the following purposes among others:

- to decide on the amount of the capital increase, the issue price (with it being hereby specified that this will be determined in accordance with the price-setting conditions stated above) and the value of the premium which may, where applicable, be demanded at the time of issue;
- to specify the dates, terms and conditions for any issue in addition to the form and characteristics of the shares or securities providing access to the capital to be issued;
- to set the dividend date, which may possibly be retroactive, of the shares or securities providing access to the capital to be issued, and the method by which they are to be paid up;
- to specify the list of beneficiaries within the above-mentioned category of persons and the number of securities to be allocated to each of them;
- at its own initiative and when it considers it appropriate, deduct the costs, duties and fees arising from the capital increases performed under the terms of the delegation mentioned in this resolution from the total premiums related to these operations and to deduct from these premiums the sums required to bring the legal reserve up to one tenth of the new share capital, after each operation,
- to confirm the performance of each capital increase and to carry out the corresponding modifications to the articles of incorporation;
- and more generally, to enter into any agreement, including to successfully complete the envisaged issues, to take all measures and carry out all formalities to facilitate the issue, the listing and the financial servicing of the securities issued under the terms of this delegation, and to exercise the attached rights;
- to take all decisions with a view to having the shares and securities thus issued listed on any exchange on which the Company's shares are traded,

decided that this delegation may not be used during periods when public offerings are underway concerning the Company's shares,

acknowledged that in the event that the board of directors uses the delegation of authority granted to it under the terms of this resolution, it will report back to the next ordinary general meeting on the use of the authorizations granted under the terms of this resolution in accordance with the law and the regulations.

Fourteenth resolution

delegation of authority to be granted to the board of directors to increase the capital by issuing ordinary shares or any other securities, without shareholders' pre-emptive subscription rights, for the benefit of a second category of persons meeting specified characteristics (up to a maximum aggregate par value of EUR 24,535,556 - industrial companies operating in the pharmaceutical, healthcare, medical technology or biotechnology sectors)

The general meeting, ruling in accordance with the quorum and majority conditions required for extraordinary general meetings,

after having acknowledged the report from the board of directors and the statutory auditors' reports,

in accordance with the provisions of articles L. 225-129 and following of the French Commercial Code and particularly its articles L. 225-129-2, L. 22-10-49, L. 225-135, L-225-138 and L. 228-91 and following of the French Commercial Code,

delegated its authority to the board of directors, for the purpose of deciding on the issuing, in one or several stages, in the proportions and at the times of its choosing, in France or abroad, in euros, in foreign currency or in any monetary units established by reference to several currencies, of ordinary shares in the Company or equity securities providing access to other equity securities or creating a right to the allocation of debt securities, and/or other securities (including all debt securities) providing access to the Company's equity securities (including in particular share subscription warrants or share issuance rights),

decided that the securities thus issued may consist of equity securities, be associated with the issuing of such securities or allow for the issue thereof as intermediate securities,

decided to remove the shareholders' preferential subscription rights to the Company's ordinary shares and/or other securities and/or all debt securities to be issued for the benefit of the following category of persons:

- industrial companies active in the health or biotechnology sector, acquiring, whether directly or via an affiliated company, a holding in the Company's equity, possibly following the conclusion of a business agreement or partnership agreement with the Company,

acknowledged, as required, that regarding the bearers of securities possibly issued, this delegation constitutes an express renunciation by the shareholders of their preferential subscription rights to the shares to which these securities create an entitlement,

decided that the maximum nominal value of the share capital increases which may be performed, immediately and/or in the future under the terms of this delegation, may not exceed 24,535,556 euros (or the equivalent of this amount in the case of an issue in another currency), which represents 2,453,555,600 shares on the basis of the current nominal value, i.e., approximately 700% of the share capital as of July 31, 2025,

being a maximum amount to which must be added, where applicable, the additional sum of the shares to be issued in order to maintain the rights of the bearers of securities providing access to the capital and other rights providing access to shares in accordance with the legal and regulatory provisions and where applicable the contractual clauses,

furthermore decided that the nominal value of any increase in share capital which may be performed will be deducted from the overall ceiling mentioned in the eighteenth resolution below,

decided to set at 24,535,556 euros (or the equivalent of this amount in the case of an issue in another currency) the maximum nominal value of the debt securities which may be issued under the terms of this delegation with it being hereby stipulated that:

- this amount will be increased, where applicable, by any redemption premium above the par value,
- this amount will be deducted from the overall ceiling mentioned in the eighteenth resolution below,
- this ceiling does not apply to the debt securities mentioned in articles L. 228-40, L. 228-36-A and L. 228-92 paragraph 3 of the French Commercial Code, the issuing of which will be decided

or authorized by the board of directors in accordance with the conditions stated in article L. 228-40 of the French Commercial Code or, in the other cases, the conditions determined by the Company in accordance with the provisions of article L. 228-36- A of the French Commercial Code,

decided that the issue price for the shares issued under the terms of this delegation will be determined by the board of directors and will be at least equal to the average market rate weighted by the volumes from the last three stock-market sessions preceding the setting of the issue price, possibly reduced by a maximum of 25%, taking account, where applicable, of their dividend date; with it being hereby specified that (i) in the event of the issuing of securities providing access to the capital, the issue price for the shares resulting from their use, their conversion or their exchange may where applicable be set at the board of directors' discretion with reference to a calculation formula defined by it and applicable after the issuing of the said securities (for example when exercising, converting or exchanging them) in which case the above-mentioned maximum reduction may be assessed, if the board considers it appropriate, on the application date of the said formula (and not the date on which the price is set for the issue) and (ii) the issue price of securities providing access to the capital possibly issued under the terms of this resolution will be such that the sum received, where applicable, immediately by the Company, increased by that likely to be received by it when exercising or converting the said securities, will be at least equal to the above-mentioned minimum sum for each share issued as a consequence of the issuing of these securities,

specified that this delegation is granted for a period of eighteen (18) months as from the date of this meeting, ending any previous delegation concerning the same subject,

decided that the board of directors will have full powers with the option of delegation and sub-delegation as stipulated by law, to implement this delegation in accordance with the conditions specified by law and in the articles of incorporation, for the following purposes among others:

- to decide on the amount of the capital increase, the issue price (with it being hereby specified that this will be determined in accordance with the price-setting conditions stated above) and the value of the premium which may, where applicable, be demanded at the time of issue;
- to specify the dates, terms and conditions for any issue in addition to the form and characteristics of the shares or securities providing access to the capital to be issued;
- to set the dividend date, which may possibly be retroactive, of the shares or securities providing access the capital to be issued, and the method by which they are to be paid up;
- to specify the list of beneficiaries within the above-mentioned category of persons and the number of securities to be allocated to each of them;
- at its own initiative and when it considers it appropriate, deduct the costs, duties and fees arising from the capital increases performed under the terms of the delegation mentioned in this resolution from the total premiums related to these operations and deduct from these premiums the sums required to bring the legal reserve up to one tenth of the new share capital, after each operation,
- to confirm the performance of each capital increase and to carry out the corresponding modifications to the articles of incorporation;
- and more generally, to conclude any agreement, including in order to successfully complete the contemplated issues, to take all measures and carry out all formalities to facilitate the issue, the listing and the financial servicing of the securities issued under the terms of this delegation, and to exercise the attached rights;

- to take all decisions with a view to having the shares and securities thus issued listed on any exchange on which the Company's shares are traded,

decided that this delegation may not be used during periods when public offerings are underway concerning the Company's shares,

acknowledged that in the event that the board of directors uses the delegation of authority granted to it under the terms of this resolution, it will report back to the next ordinary general meeting on the use made of the authorizations granted under the terms of this resolution in accordance with the law and the regulations.

Fifteenth resolution

delegation of authority to be granted to the board of directors to increase the capital immediately or in the future by issuing ordinary shares and/or securities, without shareholders' pre-emptive subscription rights, for the benefit of a category of persons meeting specified characteristics, in the context of an equity or bond financing agreement

The general meeting, ruling in accordance with the quorum and majority conditions required for extraordinary general meetings,

after having acknowledged the report from the board of directors and the statutory auditors' reports,

in accordance with the provisions of articles L. 225-129 and following of the French Commercial Code and particularly its articles L. 225-129-2, L. 22-10-49, L. 225-135, L-225-138 and L. 228-91 and following of the French Commercial Code,

delegated its authority to the board of directors, with the option of delegation or sub- delegation, in accordance with the legal conditions, for the purpose of deciding, in the proportions and the times of its choosing, on one or several capital increases through the issuing in France and abroad of ordinary shares in the Company or equity securities providing access to other equity securities or creating a right to the allocation of debt securities and/or other securities (including all debt securities) providing access to the Company's equity securities, with the possibility for the said securities to be issued in euros, in foreign currency or in any monetary units established by reference to several currencies at the choice of the board of directors, the payment for which may be in cash, including through the offsetting of receivables,

decided that the securities thus issued may consist of equity securities, be associated with the issuing of such securities (share warrants attached to bonds or issued for the benefit of subscribers of such bonds in particular) or allow for the issue thereof as intermediate securities,

decided to remove the shareholders' preferential subscription rights to the Company's ordinary shares or other securities to be issued for the benefit of the following category of persons:

- any credit establishment, any investment services provider, in addition to any investment fund or company committing itself to subscribing or guaranteeing the performance of the capital increase or of any issue of securities likely to result in a future capital increase (including through the exercising of share warrants) which may be performed under this delegation when establishing an equity or bond financing contract,

acknowledged, as required, that regarding the bearers of securities possibly issued, this delegation constitutes an express renunciation by the shareholders of their preferential subscription rights to the shares to which these securities create an entitlement,

decided that the maximum nominal value of the share capital increases which may be performed, immediately and/or in the future under the terms of this delegation, may not exceed 701,015.89 euros

(or the equivalent of this amount in the case of an issue in another currency), which represents 70,101,589 shares on the basis of the current nominal value, i.e., approximately 20% of the share capital as of July 31, 2025,

being a maximum amount to which must be added, where applicable, the additional sum of the shares to be issued in order to maintain the rights of the bearers of securities providing access to the capital and other rights providing access to shares in accordance with the legal and regulatory provisions and where applicable the contractual clauses,

furthermore decided that the nominal value of any increase in share capital which may be performed will be deducted from the overall ceiling mentioned in the eighteenth resolution below,

decided to set at 701,015.89 euros (or the equivalent of this amount in the case of an issue in another currency) the maximum nominal value of the debt securities which may be issued under the terms of this delegation with it being hereby stipulated that:

- this amount will be increased, where applicable, by any redemption premium above the par value,
- this amount will be deducted from the overall ceiling mentioned in the eighteenth resolution below. This ceiling does not apply to the debt securities mentioned in articles L. 228-40, L. 228-36-A and L. 228-92 paragraph 3 of the French Commercial Code, the issuing of which will be decided or authorized by the board of directors in accordance with the conditions stated in article L. 228-40 of the French Commercial Code or, in the other cases, the conditions determined by the Company in accordance with the provisions of article L. 228-36- A of the French Commercial Code,

decided that the issue price for the shares issued under the terms of this delegation will be determined by the board of directors and will be at least equal to the average market rate weighted by the volumes from the last three stock-market sessions preceding the setting of the issue price, possibly reduced by a maximum of 5 %, taking account, where applicable, of their dividend date; with it being hereby specified that (i) in the event of the issuing of securities providing access to the capital, the issue price for the shares resulting from their use, their conversion or their exchange may where applicable be set at the board of directors' discretion with reference to a calculation formula defined by it and applicable after the issuing of the said securities (for example when exercising, converting or exchanging them) in which case the above-mentioned maximum reduction may be assessed, if the board considers it appropriate, on the application date of the said formula (and not the date on which the price is set for the issue) and (ii) the issue price of securities providing access to the capital possibly issued under the terms of this resolution will be such that the sum received, where applicable, immediately by the Company, increased by that likely to be received by it when exercising or converting the said securities, will be at least equal to the above-mentioned minimum sum for each share issued as a consequence of the issuing of these securities,

specified that this delegation is granted for a period of eighteen (18) months as from the date of this meeting, ending any previous delegation concerning the same subject,

decided that the board of directors will have full powers with the option of sub-delegation as stipulated by law, to implement this delegation in accordance with the conditions specified by law and in the articles of incorporation, for the following purposes among others:

- to decide on the amount of the capital increase, the issue price (with it being hereby specified that this will be determined in accordance with the price-setting conditions stated above) and the value of the premium which may, where applicable, be demanded at the time of issue;

- to specify the dates, terms and conditions for any issue in addition to the form and characteristics of the shares or securities providing access to the capital to be issued;
- to set the dividend date, which may possibly be retroactive, of the shares or securities providing access the capital to be issued, and the method by which they are to be paid up;
- to specify the list of beneficiaries within the above-mentioned category of persons and the number of securities to be allocated to each of them;
- at its own initiative and when it considers it appropriate, deduct the costs, duties and fees arising from the capital increases performed under the terms of the delegation mentioned in this resolution from the total premiums related to these operations and to deduct from these premiums the sums required to bring the legal reserve up to one tenth of the new share capital, after each operation,
- to confirm the performance of each capital increase and to carry out the corresponding modifications to the articles of incorporation;
- more generally, to enter into any agreement, including in order to successfully complete the contemplated issues, to take all measures and carry out all formalities to facilitate the issue, the listing and the financial servicing of the securities issued under the terms of this delegation, and to exercise the attached rights;
- to take all decisions with a view to having the shares and securities thus issued listed on any exchange on which the Company's shares are traded,

decided that this delegation may not be used during periods when public offerings are underway concerning the Company's shares,

acknowledged that in the event that the board uses the delegation of authority granted to it under the terms of this resolution, it will report back to the next ordinary general meeting on the use made of the authorizations granted under the terms of this resolution in accordance with the law and the regulations.

Sixteenth resolution

authorization to be granted to the board of directors to increase the share capital by issuing shares and securities giving access to the Company's capital for the benefit of employees participating in the group's savings plan for the purposes of the capital increase carried out on 21 July 2025, as delegated by the general meeting of 17 July 2025

The general meeting, ruling in accordance with the quorum and majority conditions required for extraordinary general meetings,

after having acknowledged the report from the board of directors and the statutory auditors' reports, and in particular the fact that the purpose of this resolution is to regularise the capital increase decided by the board of directors on 21 July 2025 on the delegation of the general meeting of 17 July 2025,

taking note of the provisions of articles L. 3332-18 and following of the French Labor Code and ruling in accordance with the provisions of articles L. 225-129-6, L. 225-138 and L. 22-10-49 of the French Commercial Code,

delegated its authority to the board of directors, with the option of delegation, for the purpose of carrying out a capital increase, in one or several stages, in the proportions and at the times of its choosing, within a period of twenty-six (26) months as from the date of this meeting, through the issuing of a maximum of 1,400,000 shares with a par value of 0.01 euro i.e. a maximum nominal amount of 14,000 euros, to

be paid up in cash, this amount to be deducted from the ceiling mentioned in the eighteenth resolution below,

decided that this authorization shall entail the removal of the shareholders' preferential subscription rights for the cash shares to be issued for the benefit of the *Fonds Commun de Placement d'Entreprise* (employees' mutual fund) to be established as part of an employee savings plan to be created, in the event that the capital increase(s) mentioned in the previous paragraph are performed;

decided that the subscription price for the new ordinary shares, which will grant the same rights as the older shares, will be determined by the board of directors in accordance with the provisions of article L. 3332-20 of the French Labor Code; it may be neither (i) higher than the average listed rates over the twenty stock-market sessions preceding the date the decision is taken by the board of directors setting the opening date for the subscription, (ii) nor more than 30 % lower than the average listed rates over the twenty stock-market sessions preceding the date the decision is taken by the board of directors setting the opening date for the subscription or 40% when the lock-up period stated in the employee savings plan exceeds 10 years;

decided that each capital increase will only proceed for an amount equal to the value of the shares subscribed by the *Fonds Commun de Placement d'Entreprise* (employees' mutual fund);

delegated full powers to the board of directors in order to:

- specify the date and conditions for the issues to be performed under this authorization in accordance with the legal and statutory provisions, and in particular to set the subscription price, observing the rules detailed above, the opening and closure dates for the subscriptions, the dividend dates, and the dates by which the shares are to be paid up;
- confirm the performance of the capital increases up to the value of the shares which are actually subscribed;
- perform all operations and formalities, either directly or via a representative;
- amend the articles of incorporation accordingly with the share capital increases;
- and more generally do everything necessary and appropriate to complete the increase or successive increases in the share capital.

decided that this delegation may not be used during periods when public offerings are underway concerning the Company's shares,

Subject to the limits and conditions set by it beforehand, the board of directors may sub-delegate the power to decide on the performance of the issue, and to decide on its postponement, to any person authorized by law.

Seventeenth resolution

authorization to be granted to the board of directors to increase the share capital by issuing shares and securities giving access to the Company's capital for the benefit of employees participating in the group's savings plan

The general meeting, ruling in accordance with the quorum and majority conditions required for extraordinary general meetings,

after having acknowledged the report from the board of directors and the statutory auditors' reports,

taking note of the provisions of articles L. 3332-18 and following of the French Labor Code and ruling in accordance with the provisions of articles L. 225-129-6, L. 225-138 and L. 22-10-49 of the French Commercial Code,

- delegated its authority to the board of directors, with the option of delegation, for the purpose of carrying out a capital increase, in one or several stages, in the proportions and at the times of its choosing, within a period of twenty-six (26) months as from the date of this meeting, through the issuing of a maximum of 1,400,000 shares with a par value of 0.01 euro i.e. a maximum nominal amount of 14,000 euros, to be paid up in cash, this amount to be deducted from the ceiling mentioned in the eighteenth resolution below,

decided that this authorization shall entail the removal of the shareholders' preferential subscription rights for the cash shares to be issued for the benefit of the *Fonds Commun de Placement d'Entreprise* (employees' mutual fund) to be established as part of an employee savings plan to be created, in the event that the capital increase(s) mentioned in the previous paragraph are performed;

decided that the subscription price for the new ordinary shares, which will grant the same rights as the older shares, will be determined by the board of directors in accordance with the provisions of article L. 3332-20 of the French Labor Code; it may be neither (i) higher than the average listed rates over the twenty stock-market sessions preceding the date the decision is taken by the board of directors setting the opening date for the subscription, (ii) nor more than 30 % lower than the average listed rates over the twenty stock-market sessions preceding the date the decision is taken by the board of directors setting the opening date for the subscription or 40% when the lock-up period stated in the employee savings plan exceeds 10 years;

decided that each capital increase will only proceed for an amount equal to the value of the shares actually subscribed by the *Fonds Commun de Placement d'Entreprise* (employees' mutual fund);

delegated full powers to the board of directors in order to:

- specify the date and conditions for the issues to be performed under this authorization in accordance with the legal and statutory provisions, and in particular to set the subscription price, observing the rules detailed above, the opening and closure dates for the subscriptions, the dividend dates, and the dates by which the shares are to be paid up;
- confirm the performance of the capital increases up to the value of the shares which are actually subscribed;
- perform all operations and formalities, either directly or via a representative;
- amend the articles of incorporation accordingly with the share capital increases;
- and more generally do everything necessary and appropriate to complete the increase or successive increases in the share capital.

decided that this delegation may not be used during periods when public offerings are underway concerning the Company's shares,

Subject to the limits and conditions set by it beforehand, the board of directors may sub-delegate the power to decide on the performance of the issue, and to decide on its postponement, to any person authorized by law.

Eighteenth resolution

setting the overall limits on the amount of the issues carried out pursuant to resolutions 9 to 17 above

The general meeting, ruling in accordance with the quorum and majority conditions required for extraordinary general meetings,

after having acknowledged the report from the board of directors,

decided that:

- the maximum overall nominal value of the capital increases which may be performed under the delegations granted pursuant to above-mentioned 9th resolution to the 17th resolution is set at 24,535,556 euros on the basis of the current nominal value,

with it being hereby specified that this ceiling shall be increased by the additional value of the shares to be issued to preserve the rights of bearers of securities and other rights providing access to the capital, in accordance with the law, and, where applicable, the contractual clauses,

- the maximum overall nominal value of the debt securities to be issued under the delegations granted pursuant to the above-mentioned resolutions is set at 24,535,556 euros, with it being hereby specified that this amount will be increased, where applicable, by any redemption premium above par and that this ceiling does not apply to the debt securities mentioned in articles L. 228-40, L. 228-36-A and L. 228-92 paragraph 3 of the French Commercial Code, the issuing of which will be decided or authorized by the board of directors in accordance with the conditions stated in article L. 228-40 of the French Commercial Code or, in the other cases, the conditions determined by the Company in accordance with the provisions of article L. 228-36-A of the French Commercial Code.

Nineteenth resolution

Authorization to be granted to the board of directors to grant stock options or stock purchase options

The General Meeting, ruling under the quorum and majority conditions required for extraordinary general meetings,

having reviewed the report of the board of directors and the Statutory Auditors' report,

in application of the provisions of Articles 225-177 to L. 225-184 of the French Commercial Code,

authorizes the board of directors, with the option to sub-delegate to the chief executive officer, to grant, during the periods authorized by law, options giving the right to subscribe for new shares to be issued by the Company as a capital increase or to purchase existing shares of the Company, under the following conditions:

- the authorization relates to a maximum number of 17,525,000 options each relating to one share, it being recalled that in any event, the board of directors must comply with the legal limit set by Articles L. 225-182 and R. 225-143 of the French Commercial Code;
- each option will give the right to subscribe for or purchase one share of the Company with a nominal value of 0.01 euro,
- the options would be granted to members of the salaried employees and/or corporate officers (or some of them) of the Company and companies and economic interest groups linked to the Company under the conditions defined in Article L. 225-180-I of said Code,

- the total number of options thus granted would give the right to subscribe to or purchase a maximum number of 17,525,000 shares with a nominal value of 0.01 euros, i.e., a maximum nominal amount of 175,250 euros, corresponding to a maximum dilution percentage of approximately 5 % in relation to the Company's share capital on July 31, 2025,
- the purchase or subscription price per share will be set by the board of directors on the day the option is granted within the limits provided for by law and this resolution, without being lower than the average of the prices quoted on the twenty stock exchange trading days preceding the day the Board decides to grant the options, rounded up to the next euro cent, nor, in the case of purchase options, to 80% of the average purchase price of the own shares held by the Company, rounded up to the next euro cent,
- each option must be exercised within a period of 10 years at the latest from the date of their granting; it being specified, however, that this period may be reduced by the board of directors for beneficiaries resident in a given country to the extent necessary in order to comply with the law of that country,

consequently, grants full powers to the board of directors to implement this authorization and in particular, without this list being exhaustive:

- draw up a list of beneficiaries of options and the number of options allocated to each of them;
- determine the nature of the options (stock options or stock purchase options);
- set the terms and conditions of the options and determine the rules of the plan including, in particular, (i) any other performance conditions, reflecting the medium and long-term interests of the Company, and/or conditions for remaining in the group, to which the exercise of the options will be subject, if applicable, (ii) the date(s) or period(s) of exercise of the options, it being understood that the board of directors may anticipate the dates or periods for exercising the options, maintain the exercisability of the options or modify the dates or periods of non-transferability and/or non-convertibility to the bearer of the shares obtained by the exercise of the options, (iii) any clauses prohibiting the immediate resale of all or part of the shares;
- where applicable, limit, suspend, restrict or prohibit the exercise of the options or the sale or transfer to bearer form of the shares obtained by the exercise of the options during certain periods or as from certain events, and its decision may concern all or part of the options or shares or all or part of the beneficiaries;
- set the date of entitlement to dividends, even retroactively, for new shares resulting from the exercise of stock options;
- record the completion of the capital increases up to the amount of the shares which will actually be subscribed by the exercise of the subscription options, amend the bylaws accordingly, complete the subsequent formalities, and, at its sole discretion, if it deems appropriate, proceed, where applicable, to charge any costs incurred in connection with the issues against the share premium account and deduct from this account the sums necessary to fully fund the legal reserve;
- take all measures and carry out all formalities required for the listing of the new shares thus issued.

This authorization may not be used during the period of a public offer for the Company's shares.

This authorization entails, in favour of the beneficiaries of the options, the express waiver by the shareholders of their preferential subscription rights to the shares which will be issued as and when the options are exercised.

The capital increase resulting from the exercise of options will be definitively completed by the sole fact of the declaration of exercise of the option, accompanied by the subscription form and payment.

The board of directors will inform the ordinary general meeting each year of the transactions carried out under this resolution, in accordance with the provisions of Article L. 225-184 of the French Commercial Code.

This authorization, which cancels all prior authorizations to grant stock options, is granted to the board of directors for a period of thirty-eight (38) months from the date of this meeting, it being specified that the board of directors may use this authorization on one or more occasions.

Twentieth resolution

Delegation of authority to be granted to the board of directors for the purpose of issuing and allocating share subscription warrants to (i) members of the board of directors of the Company in office on the date of allocation of the warrants who are not employees or officers of the Company or one of its subsidiaries and (ii) persons bound by a service or consultancy contract to the Company or one of its subsidiaries

The general meeting, voting under the quorum and majority conditions required for extraordinary general meetings,

having read the board of directors' report and the Statutory Auditors' report,

delegates to the board of directors the authority to grant a maximum number of 17,525,000 ordinary share subscription warrants (the "SSW") each giving the right to subscribe for one share of the Company, with a nominal value of 0.01 euro, i.e., a maximum nominal amount of 175,250 euros, corresponding to a maximum dilution percentage of approximately 5% in relation to the Company's share capital on July 31, 2025,

resolves that the issue price of a SSW will be determined by the board of directors on the day of issue of said SSW based on the characteristics of said SSW, with the assistance of an independent expert,

decides to cancel, for these SSW, the shareholders' preferential subscription right, as these SSW can only be allocated to the following category of beneficiaries: (i) members of the board of directors of the Company in office at the date of grant of the warrants who are not employees or officers of the Company or any of its subsidiaries and (ii) persons who are bound by a service or consultancy contract to the Company or any of its subsidiaries (the "Beneficiaries"),

resolves, in accordance with the provisions of Article L. 225-138-I of the French Commercial Code, to delegate to the board of directors the task of determining the list of Beneficiaries and the portion of the SSW allocated to each Beneficiary so designated,

consequently, authorizes the board of directors, within the limit of the foregoing, to issue and allocate the SSW, on one or more occasions for each Beneficiary,

decides to delegate to the board of directors for each Beneficiary, the terms and conditions for exercising the SSW and, in particular, the issue price of the SSW, the exercise price and the timetable for exercising the SSW, it being specified that the SSW must be exercised within ten (10) years of their issue at the latest and that the SSW which have not been exercised at the end of this ten (10) year period will automatically become null and void,

resolves that the subscription price of an ordinary share of the Company on exercise of a SSW, which will be determined by the board of directors at the time of allocation of the SSW, must be at least equal to the volume-weighted average of the prices quoted during the 20 trading days preceding the day on

which the SSW is allocated by the board of directors,

resolves that the ordinary shares so subscribed shall be fully paid up upon subscription, either by cash payment or by set-off against liquid and due claims,

resolves that the new shares delivered to the Beneficiary upon exercise of its SSW will be subject to all provisions of the bylaws and will carry dividend rights on the first day of the financial year during which they are issued,

decides that the SSW will be transferable. They will be issued in nominative form and will be registered in an account,

resolves to issue 17,525,000 ordinary shares with a maximum par value of 0.01 euro to which the exercise of the warrants issued will give the right,

reiterates that in application of in Article L. 228-98 of the French Commercial Code:

- in the event of a capital reduction motivated by losses through a reduction in the number of shares, the rights of the holders of the SSW as to the number of shares to be received upon exercise of the SSW will be reduced accordingly as if the said holders were shareholders from the date of issue of the warrants;
- in the event of a capital reduction motivated by losses through a reduction in the nominal value of the shares, the subscription price of the shares to which the warrants entitle the holder will remain unchanged, with the issue premium being increased by the amount of the reduction in nominal value;

further resolves that:

- in the event of a capital reduction not motivated by losses by way of a reduction in the par value of the shares, the subscription price of the shares to which the warrants entitle the holder will be reduced by the same amount;
- in the event of a capital reduction not motivated by losses through a reduction in the number of shares, the holders of the SSW, if they exercise their SSW, will be able to request the repurchase of their shares under the same conditions as if they had been shareholders at the time of the Company's repurchase of its own shares,

resolves, as provided for in Article L. 228-98 of the French Commercial Code, that the Company is authorized, without having to seek the authorization of the holders of the warrants, to modify its form and corporate purpose,

recalls that pursuant to the provisions of Article L. 228-98 of the French Commercial Code, the Company is authorized to modify the rules for the distribution of its profits, amortize its capital and create preference shares entailing such modification or amortization, subject to taking the necessary steps to maintain the rights of holders of securities giving access to the capital under the conditions defined in Article L. 228-99 of the French Commercial Code,

authorizes the Company to require holders of the SSW to repurchase or redeem their rights as provided for in Article L. 228-102 of the French Commercial Code,

decides that, should it be necessary to make the adjustment provided for in Article L. 228-99 3° of the French Commercial Code, the adjustment will be performed by applying the method provided for in Article R. 228-91 of the French Commercial Code, it being specified that the value of the preferential subscription right as well as the value of the share before detachment of the subscription right will, if

necessary, be determined by the board of directors based on the subscription, exchange or sale price per share used for the last transaction involving the Company's capital (capital increase, contribution of securities, sale of shares, etc.) during the six (6) months prior to the meeting of the said board of directors or, if no such transaction is carried out during this period, according to any other financial parameter which appears relevant to the board of directors (and which will be validated by the Company's auditors),

resolves to give full powers to the board of directors to implement this delegation, in order to:

- issue and allocate the SSW and to set the subscription price, the exercise terms and conditions and the final terms and conditions of the SSW in accordance with the provisions of this resolution and within the limits set in this resolution;
- determine the identity of the Beneficiaries of the SSW as well as the number of SSW to be allocated to each of them;
- set the price of the share that may be subscribed for by exercising an SSW under the aforementioned conditions;
- record the number of ordinary shares issued following the exercise of the warrants, carry out the formalities following the corresponding capital increases and make the corresponding amendments to the bylaws;
- take all measures to ensure the protection of the holders of the warrants in the event of a financial transaction concerning the Company, in accordance with the legal and regulatory provisions in force and, where applicable, the applicable contractual stipulations;
- in general, take any measure and carry out any formality useful to this issue.

resolves that this delegation may not be used during a public offer for the Company's shares,

resolves that this delegation is granted for a period of eighteen (18) months as from this date and terminates any previous delegation having the same purpose.

Twenty-first resolution

First authorisation given to the Board to proceed with the allotment of existing or new free shares in accordance with articles L. 225-197-1 and following of the French Commercial Code

The general meeting ruling, under the conditions of quorum and majority required for extraordinary general meetings,

having taken into consideration the director's report and the report of the statutory auditors, in particular for the sake of preserving its cash, the Company intends to grant free shares in lieu of a portion of the variable compensation due to employees for the year 2024, subject to their being in the employ of the Company when the directors allot the shares;

in accordance with Articles L. 225-197-1 *et seq.* of the French Commercial Code,

authorises the Board, with the option to subdelegate this authorisation to the chief executive officer, to make a free grant of the Company's existing or future shares, on one or more occasions, to members of the Company's salaried staff, or certain categories of them and/or its corporate officers who satisfy the conditions set by Article L.225-197-1, II of the French Commercial Code as well as to members of the salaried staff of the companies or economic interest groups in which the Company directly or indirectly holds at least 10% of the capital or voting rights on the date these shares are allotted;

stipulates that if the shares of the Company are trading on a regulated market, the Board must allocate free shares to officers who meet the conditions set by Article L.225-197-1, II of the French Commercial Code, in order to comply with the provisions of Article L. 225-197-6 of the French Commercial Code;

decides to set at 3,505,079 shares, each of a nominal value of €0.01, representing a nominal amount of €35,051, the total number of bonus shares that may be granted by the Board under this authorisation, corresponding to a maximum dilution percentage of 1% in relation to the Company's share capital as at July 31, 2025, excluding the nominal amount of the shares to be issued, as the case may be, in respect of the adjustments made in accordance with the law and any applicable contractual provisions;

decides that the allocation of shares to their beneficiaries will be final, subject to fulfilling the conditions or criteria set by the board of directors, after a period of at least one (1) year (the "Vesting Period"), and that the beneficiaries of these shares must hold them for a period of time set by the board of directors (the "Holding Period"), which, together with the Vesting Period, may not be less than two (2) years;

specifies that (i) this authorisation may only be implemented by the board of directors for the purpose of allocating a maximum number of free shares per beneficiary, based on the average price of the last 20 trading days preceding their allocation, representing a value equal to 50% of the maximum individual variable remuneration of the person concerned for the 2023 financial year, provided it has not already been paid to him in cash and that (ii) the final vesting of the said free shares by the beneficiaries concerned will not be subject to performance conditions;

decides that, as an exception to the above, the shares will be permanently allotted before the end of the Vesting Period if the beneficiary becomes disabled with a 2nd or 3rd category disability under Article L.341-4 of the French Social Security Code;

decides that the allocated shares will be freely transferable upon a request for allocation by the heirs of a deceased beneficiary or a beneficiary that becomes disabled under the aforementioned categories of the French Social Security Code;

decides that the duration of the Vesting Period and retention period shall be determined by the Board within the aforementioned limits;

takes note that in accordance with Article L.225-197-1 of the French Commercial Code, if the allocation concerns shares to be issued, this authorisation automatically entails the shareholders waiving their preferential subscription right in favour of the beneficiaries of the free shares, the corresponding capital increase being carried out solely by the permanent allocation of shares to the beneficiaries;

takes note, for the sake of clarity, that this decision entails the waiver, by the shareholders in favour of the beneficiaries of free shares, of the part of the reserves, profits, or premiums that will be used to issue new shares, if need be, at the end of the Vesting Period, for which full powers are delegated to the board of directors;

delegates all powers to the board of directors in order to:

- establish that sufficient reserves exist and, for each allotment, transfer the funds required for paying up the new shares to be allotted, to an unavailable reserve account;
- decide the identity of the beneficiaries of the allotments and the number of bonus shares to be allotted to each of them;
- determine the conditions and if necessary the criteria for allotting the shares;

if necessary:

- decide, when the time comes, the capital increase(s) corresponding to the issue of any new grant of free shares;
- acquire the shares necessary for the delivery of any existing shares allotted free of charge;
- take all measures to ensure that the beneficiaries respect the holding obligation; and
- generally, within the context of the legislation in force, carry out all that the implementation of this authorisation requires;

this authorisation cannot be used while a takeover bid for the Company is in progress;

This authorisation, which cancels any previous authorisation to allocate bonus shares, is given to the board of directors for a period of 38 months from the date of this general meeting, it being specified that the board of directors may use this authorisation on one or more occasions.

Twenty-second resolution

Second authorisation to be given to the Board to proceed with the free allocation of existing shares or shares to be issued in accordance with articles L. 225-197-1 and following of the French Commercial Code

The general meeting ruling, under the conditions of quorum and majority required for extraordinary general meetings,

having taken into consideration the directors' report and the report of the statutory auditors, in particular, for the sake of preserving its cash and maintaining its key personnel, the Company intends to grant free shares in lieu of a portion of the variable compensation due to employees for the year 2025, subject to their employ in Company at the time the Board allocates the shares, and to provide an attractive retention plan;

In accordance with Articles L.225-197-1 *et seq.* of the French Commercial Code,

authorises the Board ,with the option to subdelegate this authorisation to the chief executive officer, to make a free grant of the Company's existing or future shares, on one or more occasions, to members of the Company's salaried staff, or certain categories of them and/or its corporate officers who satisfy the conditions set by Article L.225-197-1, II of the French Commercial Code as well as to members of the salaried staff of the companies or economic interest groups in which the Company directly or indirectly holds at least 10% of the capital or voting rights on the date these shares are allotted;

stipulates that if the shares of the Company are trading on a regulated market, the Board must allocate free shares to officers who meet the conditions set by Article L.225-197-1, II of the French Commercial Code, in order to comply with the provisions of Article L. 225-197-6 of the French Commercial Code;

decides to set at 3,505,079 shares, each with a nominal value of €0.01, representing a total nominal amount of €35,051, the total number of bonus shares that may be allocated by the Board pursuant to this authorisation, corresponding to a maximum dilution percentage of 1% in relation to the share capital of the Company as at July 31, 2025, it being specified that (i) the total number of bonus shares awarded by the Board can never exceed the global limit of 10% of the Company's existing capital on the date of the decision to grant them and (ii) the nominal amount of the capital increases resulting from the allocation of free shares that may be granted under this authorisation and from the 20th resolution above and the exercise of stock options granted under the terms of the 18th resolution and the exercise of the subscription warrants granted in the 19th resolution hereabove, may not exceed a nominal amount of €175,250, representing a maximum of 17,525,000 shares, corresponding to a maximum dilution percentage of approximately 5% in relation to the share capital of the Company as at July 31, 2025,

excluding the par value of securities to be issued, as the case may be, for adjustments made in accordance with the law and, as the case may be, applicable contractual stipulations;

decides that the allocation of the shares to their beneficiaries will be final, subject to meeting any conditions or criteria set by the board of directors, at the end of a period of at least one (1) year (the "Vesting Period"), and that the beneficiaries of these actions should, as appropriate, hold them for a period of time set by the board of directors (the "Holding Period", which, combined with that of the Vesting Period may not be less than two (2) years, and it being specified that, in the case of bonus shares granted to executive corporate officers, their allocation will be final subject to meeting the following performance conditions, assessed over the short or medium term: advancing the Company's three key programmes of expanding the portfolio through strategic transactions, share price performance, and financing and organising the Company; these performance criteria and their weighting being identical to those used to determine the chief executive officer's variable compensation;

decides that, as an exception to the above, the shares will be permanently allotted before the end of the Vesting Period if the beneficiary becomes disabled with a 2nd or 3rd category disability under Article L.341-4 of the French Social Security Code;

Decides that the allocated shares will be freely transferable upon a request for allocation by the heirs of a deceased beneficiary or a beneficiary that becomes disabled under the aforementioned categories of the French Social Security Code;

decides that the duration of the Vesting Period and retention period shall be determined by the Board within the aforementioned limits;

takes note that in accordance with Article L.225-197-1 of the French Commercial Code, if the allocation concerns shares to be issued, this authorisation automatically entails the shareholders waiving their preferential subscription right in favour of the beneficiaries of the bonus shares, the corresponding capital increase being carried out solely by the permanent allocation of shares to the beneficiaries;

takes note, for the sake of clarity, that this decision entails the waiver, by the shareholders in favour of the beneficiaries of free shares, of the part of the reserves, profits, or premiums that will be used to issue new shares, if need be, at the end of the Vesting Period, for which full powers are delegated to the board of directors;

delegates all powers to the board of directors in order to:

- establish that sufficient reserves exist and, for each allotment, transfer the funds required for paying up the new shares to be allotted, to an unavailable reserve account;
- decide the identity of the beneficiaries of the allotments and the number of free shares to be allotted to each of them;
- determine the conditions and if necessary, the criteria for allotting the shares;

if necessary:

- decide, when the time comes, the capital increase(s) corresponding to the issue of any new grant of bonus shares;
- acquire the shares necessary for the delivery of any existing shares allotted free of charge;
- take all measures to ensure that the beneficiaries respect the holding obligation; and
- generally, within the context of the legislation in force, carry out all that the implementation of

this authorisation requires;

this authorisation cannot be used while a takeover bid for the Company is in progress;

This authorisation, which cancels any previous authorisation to allocate bonus shares, is given to the board of directors for a period of 38 months from the date of this general meeting, it being specified that the board of directors may use this authorisation on one or more occasions.

Under the competence of the ordinary and extraordinary general meeting

Twenty-third resolution

powers to carry out formalities

The general meeting, ruling in accordance with the quorum and majority conditions required for extraordinary and ordinary general meetings,

gave full powers to the bearer of an original, copy or extract of the present document to carry out all the formalities of publication and filing required by the legislation in force.

* * *

BUSINESS OVERVIEW IN 2024

Valerio Therapeutics (formerly Onxeo) is a clinical-stage biotechnology company developing innovative drug candidates using two proprietary platforms: the PlatON platform and its unique DNA decoy mechanism of action, and the V-Body platform generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

Valerio Therapeutics is listed on Euronext Growth in Paris.

The Company's portfolio includes:

- **platON™** is Valerio Therapeutics proprietary chemistry platform of DNA decoy therapeutics, which generates new innovative compounds and broaden the Company's product pipeline.
- **AsiDNA™**, the first compound from platON™, is a highly differentiated, clinical-stage first-in-class candidate in the field of DNA damage response (DDR) applied to oncology. Its DNA decoy therapeutic mechanism acting upstream of multiple DDR pathways results in distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and strong synergy with tumor DNA-damaging agents such as radiotherapy and chemotherapy. Clinical development of AsiDNA has been discontinued in order to redirect research and development efforts to next-generation drug candidates from both the PlatON and V-Body platforms.
- **VIO-01** (formerly OX425), the second compound from platON™, is a novel pan-DDR Decoy with high antitumor activity. It also mediates multiple immunostimulatory effects by activating the STING pathway. In 2024, VIO-01 underwent a first phase 1 clinical development trial in the United States. Clinical development of VIO-01 was halted in early 2025 in order to redirect research and development efforts to next-generation drug candidates from both the PlatON and V-Body platforms.
- **DecoyTAC** : the 3rd generation platON™ platform, leveraging the unique MOA of DNA decoy therapeutics coupled to targeted protein degradation (PROTAC). This evolution expands the activity of platON™ platform beyond DNA repair by targeting other proteins such as transcription factors, in oncology and outside oncology for other diseases like inflammatory and muscular diseases. In 2024, a first proof of concept was generated by targeting the c-myc oncoprotein.
- **V-bodies Platform**: The acquisition of Emglev Therapeutics (owned by Valour Bio, a subsidiary of Valerio Therapeutics) enabled the use of phage display technology to produce single-domain antibodies, called V-bodies, from proprietary synthetic libraries. These V-bodies differ from traditional antibodies in that they are significantly smaller, approximately one-tenth that of conventional antibodies. This size advantage allows them to penetrate tissues more rapidly and reach targets that are typically difficult to access, while retaining the binding and/or neutralizing functions of a full-length antibody.

Furthermore, Valour Bio's proprietary libraries are humanized or fully human, meaning they have been engineered to reduce the potential for immunogenicity and toxicity. This humanization process improves their compatibility with the human immune system, potentially making them more tolerable as therapeutic agents for patients.

The versatility of V-bodies allows them to target a wide range of antigens, expanding their therapeutic applicability. Single-domain antibodies (Sd-Abs) have demonstrated strong potential in various pathologies, including autoimmune diseases, inflammatory conditions, and cancer. Their ability to efficiently bind to a variety of targets makes them valuable tools for the development of antibody-based therapies for the most complex diseases.

V-bodies can be used in several therapeutic formats, such as bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR-T) cells engrafted into T cells. Antibody-drug conjugates are particularly noteworthy because they can deliver various types of payloads, including radioisotopes, chemotherapeutic agents, small molecules, or oligonucleotides. This diversity of payloads expands the potential applications for different patient populations, making V-bodies a promising platform in biomedicine. Furthermore, V-bodies can potentially be administered via various routes, such as subcutaneous, inhaled, oral, or intravenous, offering a significant improvement over traditional antibodies, which generally require intravenous administration. Overall, Valour Bio's approach with V-bodies represents a major advancement in the field of antibody-based therapies, providing potential solutions to the critical limitations of conventional antibodies.

Optimizing the PlatON Platform with V-bodies:

The main challenges faced by the PlatON platform's DNA decoys are their short half-life and specific delivery. Combining the V-body platform with the PlatON platform will leverage these two innovations by:

- Extending half-life with an anti-albumin V-body conjugated to the DNA decoys.
- Increasing specificity by using V-bodies targeting tissue-specific receptors for delivery, conjugated to the DNA decoys.

The Company is convinced that these technologies have significant therapeutic potential and represent a disruptive innovation that could pave the way for a new paradigm of treatment of diseases in the field of oncology, rare diseases and inflammatory and autoimmune diseases.

1. R&D PROGRAMMES

1.1. VIO-01

VIO-01, formerly OX425, is a Pan-DDR DNA Decoy Targeting Multiple Proteins & Repair Pathways and represents the most optimal drug candidate selected to enter clinical development. VIO-01 traps several DDR Proteins Inhibiting Different DNA Repair Pathways. VIO-01 reaches the nucleus and acts as a decoy for several DNA repair enzymes. It has an increased resistance to nucleases and plasmatic stability.

VIO-01 underwent late-stage IND-enabling preclinical development in 2023, with the execution of regulatory toxicology and ADME/PK studies. This package allowed IND submission to FDA followed by approval to start first-in-human clinical trial which started in January 2024.

NEXT Oncology San Antonio, the first site for the Phase 1/2 study (VIO-01-101) of VIO-01, was activated and the first patient was treated in January 2024. In the first half of 2024, VIO-01 was evaluated in six patients at two different doses, with an encouraging safety profile.

Clinical development of VIO-01 was discontinued in early 2025 to redirect research and development efforts toward next-generation drug candidates based on the PlatON and V-Body platforms.

1.2.3RD GENERATION OF PLATON™ PLATFORM

Valerio Therapeutics continued to optimize the PlatON™ platform to develop more potent assets coupled to innovative technologies, with the objective to combine PlatON™ platform's DNA decoys with the targeted protein degradation strategy offered by PROTACs (PROteolysis-TArgeting Chimeras) technology. PROTACs technology and other tumor specific targeting options may be a novel class of hetero-bifunctional molecules that can selectively degrade target proteins within cells. This approach offers several advantages over the other molecules involved in modulating the DNA damage response, such as increased selectivity and reduced toxicity. This specific strategy involves generating DecoyTAC combining our vectorized DNA decoy molecules capable of efficient cell penetration with a linker+E3 ligand promoting the complete degradation of the target proteins, thereby presenting a novel mechanism of action.

The exploration of the convergence of PROTACs and DNA Decoys aims to not only propose new therapeutic modalities against DDR proteins but also against transcription factor proteins that are challenging to target. A first proof of concept was demonstrated by targeting the cMYC oncoprotein. Through these efforts, the Company strives to advance the field of drug development and contribute to the treatment of patients with pathologies with a real therapeutic need.

1.3.NEW V-BODY PLATFORM


Valour Bio's platform will enable the diversification and expansion of the company's portfolio into other oncology targets, as well as beyond oncology, particularly in autoimmune, inflammatory, and rare genetic diseases. The assets generated through the PlatON platform (DNA decoys), the V-body platform (bispecifics, ADCs, CAR-T), or both combined (V-body-oligonucleotide conjugates) will revolutionize our approach to these diseases and bring added value to the company by attracting diverse investors and facilitating future fundraising. The last quarter of 2024 allowed the internalization of the various expertise and technologies associated with this new platform and the initial proof-of-concept experiments to be conducted.

1.4.EVOLUTION OF THE R&D PORTFOLIO

Developments compared to the portfolio presented in the 2024 annual report are as follows:

- Phase 1/2 of the VIO-01 clinical study in the United States began with the enrollment of six patients in the first half of 2024. Following the evolution of the R&D strategy, this study was closed in January 2025 to refocus the company on optimizing the new platforms.
- Initial proofs of concept with DecoyTAC technology (3rd generation platON platform)
- Internalization of the new V-body platform

As of July 8, 2025, the Company's R&D portfolio is as follows:



2. FUNDING

On April 30, 2024, Valerio Therapeutics has received a €5 million financing commitment from its main shareholders, Artal International SCA and Financière de la Montagne. This commitment was made in the form of a shareholder current account in May 2024, providing the Company with a cash flow horizon through the end of 2024.

Part of this financing was used by Valerio Therapeutics to complete the acquisition of Emglev Therapeutics, for an amount of 2.5 million euros.

Valerio Therapeutics used a portion of this financing to complete the acquisition of Emglev Therapeutics for €2.5 million (a portion of which was paid in shares). The acquisition was made through its subsidiary Valour Bio. The remainder of the financing was used to cover Valerio Therapeutics' ongoing operations and the development of the new Emglev platform.

At the end of 2024, a reduction in the Company's operating expenses enabled it to extend its cash flow horizon by approximately three months. Furthermore, in 2025, in addition to reducing its expenses, the Company negotiated with various stakeholders and obtained an agreement to secure its financial and cash flow trajectory until at least the end of 2025.

3. GOVERNANCE

The Annual General Meeting of June 4, 2024 renewed the mandate of directors of Ms. Shefali Agarwal and Mr. Bryan Giraudo for a period of three years.

At a meeting held on November 13, 2024, the Board of Directors of Valerio Therapeutics decided to appoint Mr. Julien Miara as Chief Executive Officer and Chairman of the Board of Directors of Valerio Therapeutics, succeeding Ms. Shefali Agarwal.

At a meeting held on November 20, 2024, the Board of Directors of Valerio Therapeutics acknowledged the resignation of Mr. Robert L. Coleman from his position as director.

At a meeting held on November 21, 2024, the Board of Directors of Valerio Therapeutics decided to appoint Mr. Antoine Barouky as Deputy Chief Executive Officer of the Company.

As of December 31, 2024, the Board of Directors was composed of 6 members, including 2 independent members.

The Board of Directors, on February 20, 2025, decided to separate the roles of Chairman of the Board and Chief Executive Officer. GammaX Corporate Advisory resigned and its Chairman, Mr. Jacques Mallet, was appointed Chairman of the Board of Directors. Mr. Julien Miara was confirmed as Chief Executive Officer of the Company. Mr. Khalil Barrage resigned as a director of the Company and Mr. Antoine Barouky was co-opted as a director.

The extraordinary general meeting of April 9, 2025, ratified the appointment of Mr. Jacques Mallet and Mr. Antoine Barouky, and terminated the mandate of Ms. Shefali Agarwal as director.

As of September 8, 2025, the Board of Directors is composed of five members, including one independent member.

Detailed information on governance can be found in the corporate governance report presented in the 2024 annual report.

4. CHRONOLOGICAL SUMMARY OF THE COMPANY'S PRESS RELEASES IN FISCAL YEAR 2024

The full text of these press releases can be accessed on the Company website at (www.valeriotx.com).

January 25, 2024	Half-yearly report on the liquidity contract of Valerio Therapeutics
February 5, 2024	Valerio Therapeutics announces capital reduction driven by losses through reduction in par value of company shares
April 30, 2024	Availability of the 2023 annual report
May 22, 2024	Valerio Therapeutics Provides Clinical Development Update on its Phase 1/2 VIO-01 Clinical Trial
September 29, 2024	Half-yearly report on the liquidity contract entered into with Kepler Cheuvreux
September 30, 2024	Valerio Therapeutics Announces First Half 2024 Financial Results and Provides Business Update
September 30, 2024	Valerio Therapeutics Acquires Emglev Therapeutics, a Single Domain Antibody Therapies Company
November 15, 2024	Valerio Therapeutics S.A. Board of Directors Meeting of November 13, 2024

5. SIGNIFICANT EVENTS AFTER DECEMBER 31, 2024

On **February 3, 2025**, the Company announced the strategic decision to discontinue all clinical trials and related activities, including the ongoing VIO-01 trial. This decision was made by the Board of Directors in response to the Company's financing challenges. The completion of clinical trials will allow the Company to focus exclusively on early-stage drug development, ensuring efficient use of available capital while maintaining a strong focus on innovation. As part of this transition, the Company will cease its oncology clinical-stage activities and close its U.S. office in Lexington, MA.

On **February 27, 2025**, the Company announced that it had terminated the liquidity agreement entered into on October 29, 2018, with KEPLER CHEUVREUX. The termination took effect on February 19, 2025. This termination was decided as part of the savings realized by the Company given its cash position. The Company does not plan to enter into another liquidity agreement at this stage.

On **May 5, 2025**, the Company announced the postponement of the publication of its 2024 annual financial report, initially scheduled for April 30, 2025, and of the closing and approval of its 2024 statutory and consolidated financial statements, due in particular to significant difficulties in accessing the accounting elements of its subsidiary in the United States, Valerio Therapeutics Inc.

Although the assets relating to this subsidiary are depreciated in the Company's statutory financial statements and it ceased all activity at the end of 2024, this delay in the accounting treatment of Valerio Therapeutics Inc. does not allow the Company to finalize its statutory and, a fortiori, consolidated financial statements.

Consequently, the Company's 2024 consolidated and statutory accounts and the publication of the 2024 annual financial report will not be able to take place before the end of July 2025. The Company's 2024 annual accounts will be approved in September 2025.

On **June 12, 2025**, the Company announced, regarding the development of its financial situation, that it had finalized an agreement to extend the maturity of its bank debts and to reduce or stagger its debts to its main suppliers.

The Company's main shareholders, Artal International SCA and Financière de la Montagne, have made advances that should be incorporated into the capital in the amount of five million five hundred thousand euros in order to meet the Company's short-term needs and finance its activities at least until the end of 2025 (it being specified that part of this envelope has already been used to settle the Company's debts). The Company's financial situation remains precarious, however, and a long-term and sustainable financing solution is still being sought.

On **June 24, 2025**, the Company announced the temporary suspension of trading of its shares on Euronext as of June 17, 2025, following the delay in the publication of the annual financial report for the year ended December 31, 2024. The Company reminds its shareholders that the publication of the 2024 annual financial report has been postponed due to significant difficulties in accessing the accounting information of its U.S. subsidiary, Valerio Therapeutics Inc. Valerio Therapeutics is currently finalizing its statutory and consolidated financial statements. The report will be published after the certification of the accounts by the statutory auditors.

Trading in Valerio Therapeutics shares on Euronext Growth in Paris is expected to resume after publication of this report. The Company will inform the market as soon as possible of the new publication date of the 2024 annual financial report, the final date of the general meeting, and the effective date of resumption of trading.

On **July 10, 2025**, the Company announced the resumption of trading of its shares from the opening of the markets on July 10, 2025. Following the validation by Euronext, this resumption of trading follows the publication, on July 9, 2025, of its annual financial report for the financial year ending December 31, 2024.

On **July 22, 2025**, the Company announced the completion of several transactions on its share capital with a view to restructure part of its liabilities. The Company's Board of Directors meeting on 21 July 2025 took the following decisions:

- **Capital reduction motivated by losses through a reduction in the nominal value of shares**

Exercising the delegation granted by the General Meeting of 17 July 2025, the Board of Directors of 21 July 2025 decided to proceed with a capital reduction by clearing part of the losses in the amount of €20,067,355.47. This capital reduction motivated by losses was carried out by reducing the nominal value of the Company's shares from €0.14 to €0.01. This transaction had no impact on the number of shares in circulation. Following this transaction, the Company's share capital amounted to €1,543,642.73, divided into 154,364,273 ordinary shares with a nominal value of €0.01 each.

- **Conversion of convertible bonds by Financière de la Montagne**

As a reminder, the Board of Directors, exercising the powers delegated to it under the terms of the 13th resolution of the General Meeting of 10 June 2021, decided on 6 April 2022 to issue a convertible bond loan with a nominal value of €4,000,000 through the issue 4,000,000 convertible bonds (the 'CBs') with a nominal value of €1 each and to reserve the subscription to Financière de la Montagne for an amount of 1,500,000 euros. The CBs Issue Agreement was entered into between the Company and Financière de la Montagne on 20 April 2022.

Pursuant to the CBs Issue Agreement, the Company sent Financière de la Montagne a notice of exercise of the CBs for the purpose of converting the 1,500,000 CBs it holds into 27,777,777 ordinary shares of the Company with a par value of €0.01 (following the aforementioned capital reduction), at a price of €0.054 calculated in accordance with the CBs Issue Agreement (volume-weighted average price of the last three trading days preceding the exercise of the Convertible Bonds, rounded down to the third decimal).

Exercising the delegation granted by the General Meeting, the Board of Directors meeting on 21 July 2025 noted the conversion by Financière de la Montagne of 1,500,000 convertible bonds into 27,777,777 ordinary shares of the Company with a par value of €0.01 each, and, as a result, the completion of a capital increase with a nominal value of €277,777.77, for the benefit of Financière de la Montagne. Following this transaction, the Company's share capital amounted to €1,821,420.50, divided into 182,142,050 ordinary shares with a par value of €0.01 each.

• **Capital increase through offset of receivables**

Exercising the delegation granted by the General Meeting of 17 July 2025, the Board of Directors of 21 July 2025 decided to proceed with a capital increase of a nominal amount of €1,683,658.93 through receivables offset by issuing 168,365 893 new ordinary shares with a par value of €0.01 each, with the preferential subscription right being waived in favour of certain categories of investors.

The subscription price for the new shares was set at €0.046 per share (including an issue premium of €0.036 per share), corresponding to the volume-weighted average price of the last three trading days on the regulated market of Euronext Growth Paris (the trading days of 16, 17 and 18 July 2025, i.e. €0.054), less a 15% discount, in accordance with the delegation granted by the General Meeting, representing a total subscription amount, including the issue premium, of €7,744,831.08.

The subscription to this capital increase was carried out in full by offsetting receivables with current accounts held in particular by Artal International SCA, Financière de la Montagne and SCP Esperanza 2019.

Following completion of all of the above transactions, the Company's share capital amounts to €3,505,079.43, divided into 350,507,943 ordinary shares with a par value of €0.01 each.

TERMS OF PARTICIPATION IN THE GENERAL MEETING

All shareholders, regardless of the number of shares they own, are entitled to attend the meeting.

Justification of the right to participate in the general meeting

The right to attend the meeting is evidenced by the registration of the shares in the name of the shareholder or of the intermediary registered on the shareholder's behalf, on **September 26, 2025, at 00:00** Paris time, either in the registered share accounts held by Société Générale, or in the bearer share accounts held by an authorized intermediary.

The registration of shares in bearer share accounts held by an authorized intermediary is evidenced by a certificate of participation issued by the intermediary, appended to the absentee voting or proxy form or the request for an admission card drawn up in the name of the shareholder or on behalf of the shareholder represented by the registered intermediary. A certificate is also issued to shareholders wishing to attend the meeting in person who have not received their admission card by midnight Paris time on **the second business day** prior to the meeting.

How to attend the meeting

1. Shareholders wishing to attend the meeting in person:
 - Registered shareholders should request an admission card by sending the duly completed postal voting form, using the prepaid envelope enclosed with the notice of meeting, or by post to Société Générale Securities Services (Service Assemblées, CS 30812, 44308 Nantes Cedex 3); if they have not received their admission card by the **second business day** prior to the meeting, they may go directly to the appropriate counter on the day of the meeting, with proof of identity.
 - Holders of bearer shares should ask the authorized intermediary managing their share account to send them an admission card.
2. Shareholders not attending the meeting in person and wishing to vote by post or by proxy
 - For registered shareholders: return the single postal voting form or proxy form, which will be sent with the notice of meeting, either by post using the T envelope enclosed with the notice of meeting to the following address: Société Générale - Service assemblées - 32 rue du Champ de Tir, CS 30812, 44308 Nantes cedex 3, or by e-mail to ag2025@valeriotx.com;
 - For holders of bearer shares: request this form from the intermediary who manages their shares, as from the date on which the meeting is called. The single postal or proxy voting form must be accompanied by a certificate of participation issued by the financial intermediary and returned by the latter by post to the following address Société Générale - Service assemblées - 32 rue du Champ de Tir, CS 30812, 44308 Nantes cedex 3 or by e-mail to ag2025@valeriotx.com.

Requests for voting forms must reach Société Générale **via the shareholder's financial intermediary**, at one of the addresses indicated above, at least six days before the scheduled date of the meeting, i.e. **September 24, 2025**.

Only duly completed voting forms received by Société Générale and/or the Company by email, at one of the above addresses, at least **three days** before the date of the Meeting, i.e. by **11:59 p.m. on September 27, 2025** at the latest, and accompanied by the certificate of participation issued by the authorized intermediaries, will be taken into account in the case of bearer shares.

Shareholders wishing to appoint a proxy

In accordance with the provisions of Article R. 225-79 of the French Commercial Code, notification of the appointment and revocation of a proxy may be made electronically, as follows:

- For registered shareholders: the shareholder must send an e-mail to the following e-mail address: ag2025@valeriotx.com, specifying his or her surname, first name, address and Société Générale identifier for pure registered shareholders (information available at the top left of the account statement) or his or her identifier with his or her financial intermediary if he or she is an administered registered shareholder, as well as the surname, first name and address of the appointed or revoked proxy;
- For bearer shareholders: the shareholder must send an e-mail to the following address: ag2025@valeriotx.com, specifying his or her surname, first name, address and bank details, as well as the surname, first name and address of the appointed or revoked proxy. **The shareholder must then ask the financial intermediary managing his or her securities account to send written confirmation to Société Générale, Services Assemblées, 32 rue du Champ de Tir, CS 30812, 44308 Nantes cedex 3.**

In order for duly signed and completed proxy designations or revocations to be validly taken into account, they must reach the Company or Société Générale no later than **three days** before the date of the Meeting, i.e. **by 11:59 p.m. on September 27, 2025** at the latest, regardless of whether notifications are made electronically or by post.

Any shareholder who has already cast a vote, sent a proxy or requested an admission card or certificate of attendance:

- can no longer choose another method of participation;
- may sell all or part of its shares at any time. If the sale takes place before **September 26, 2025 at 00:00**, Paris time, the company will invalidate or amend, as appropriate, the absentee ballot, the proxy, the admission card or the certificate of attendance. To this end, the authorized intermediary holding the shares will notify the Company or its agent of the sale, and provide the necessary information.

Written Questions

Any shareholder may also submit a written question. These questions must be sent:

- to the registered office at 49 Boulevard du Général Martial Valin, 75015 Paris, by registered letter with acknowledgment of receipt, addressed to the chairman of the board of directors,
- to the following email address: ag2025@valeriotx.com,

no later than **four business days** before the general meeting, i.e., no later than **September 24, 2025**, accompanied by a certificate of registration in either the registered share accounts or the bearer share accounts held by the authorized intermediary.

Shareholders' right to information

In accordance with the law, all documents required to be communicated at general meetings will be made available to shareholders at the registered office within the legal timeframe. These documents will be available for consultation on the Company's website www.valeriotx.com.

The Board of Directors

REQUEST FOR THE SENDING OF ADDITIONAL DOCUMENTS
--

Concerning the Annual General Meeting of September 30, 2025

I, the undersigned : :

NAME :

First name :

Adress :

Owner of _____ registered shares

Owner of _____ bearer shares

Of VALERIO THERAPEUTICS

hereby acknowledge having received the documents relating to the above-mentioned General Meeting and referred to in Article R.225-81 of the French Commercial Code,

request that the documents and information concerning the Annual General Meeting of September 30, 2025, as referred to in Article R.225-83 of the French Commercial Code, be sent to me.

_____, _____ 2025.

Signature

* In accordance with article R. 225-88 paragraph 3 of the French Commercial Code, holders of registered shares may, by means of a single request, obtain from the Company the documents and information referred to in articles R. 225-81 and R. 225-83 of the French Commercial Code, on the occasion of each subsequent general meeting. Should a shareholder wish to take advantage of this option, he or she must indicate this on the request form.